Wasp family protein fragments, and use thereof

ABSTRACT

The invention concerns peptide fragments of the WASP family proteins, or peptides derived from said fragments, and their uses in particular for preparing reagents for use in implementing a method for detecting or screening molecules with inhibiting or stimulating effect on the formation of the actin cytoskeleton, hence an inhibiting or stimulating effect on cellular motility.

[0001] The invention concerns peptide fragments of WASP family proteins or peptides derived from these fragments, and uses thereof in particular within the context of molecule detection processes having an effect on cellular motility.

[0002] The cells of our body are capable of moving and they sometimes become round and divide into two sister cells. All these movements are based on the actin cytoskeleton. At a multicellular stage, the cytoskeleton plays an essential role in the organisation of the body and homeostasis. For example, cellular migration is essential in embryogenesis and the immune response, as well as in the healing of wounds, where the cells migrate to the damaged regions. These movements are dependent on the normal functioning of the actin cytoskeleton. The consequences of disturbing the functioning of the cytoskeleton can be disastrous to the organism. In metastatic processes, for example, the cytoskeleton's lack of control over tumorous cells can cause them to migrate outside their normal location, allowing them to proliferate in other parts of the body, which makes treatment of the cancer extremely difficult.

[0003] The characterisation of proteins capable of polymerising actin and the understanding of the mechanism whereby this polymerisation generates a force, represent the key elements in understanding the functioning of the cytoskeleton in the cell. However, the dynamic properties of the cytoskeleton make it extremely difficult to study. Moreover, the approaches currently available for analysing the cytoskeleton are complicated or tedious.

[0004] The first stage in all the processes dependent on the cytoskeleton, such as movement, is the production of filaments of actin, or F-actin. The mechanism of the formation of these biological polymers in the cell is still not known, despite the identification of numerous actin-binding proteins, and the extensive study of actin polymerisation in vitro.

[0005] Wiskott-Aldrich syndrome is a disease of the cytoskeleton. Human WASP protein, expressed on the basis of the WAS gene which is mutated in patients affected by this syndrome, and likewise N-WASP protein of bovine origin (which is approx. 45% identical in sequence with human WASP protein) have thus been the subject of investigations aimed at explaining the mechanism of the functioning of the cytoskeleton in the cell (Yarar et al., Current Biology, 9: 555-558 (1999); Rohatgi et al., Cell, 97: 221-231 (1999); Miki et al., The EMBO Journal, 15(19): 5326-5335 (1996)).

[0006] These WASP and N-WASP proteins are made up of peptide domains having functional properties which are identifiable in biochemical tests. Thus, these two proteins mainly possess the following domains:

[0007] a plekstrin homology domain which binds to phosphatidylinositol (4,5) biphosphate, the latter itself binding to proteins involved in the formation of actin filaments,

[0008] a Cdc42 binding domain, a protein with GTPase activity inducing actin polymerisation, and hence regulating the cytoskeleton,

[0009] a prolin-rich region,

[0010] a verprolin homology domain, a protein also binding to proteins involved in the formation of actin filaments, said domain comprising a verprolin-homologous sequence in the case of human WASP, and two verprolin-homologous sequences in the case of N-WASP,

[0011] a cofilin homology domain, an actin-binding protein, having an actin-depolymerisation activity dependent on the pH,

[0012] a C-terminal acid segment.

[0013] Moreover, it has been shown that these WASP and N-WASP proteins interact with the Arp2/3 complex (a proteic complex involved in actin polymerisation) and thus induce actin polymerisation.

[0014] On this basis, it has been demonstrated that WASP protein is sufficient to act on cellular motility based on actin, and that this function is dependent on the Arp2/3 complex (Yarar et al. 1999, mentioned above). To demonstrate this, the authors of this article prepared microspheres covered with WASP protein and demonstrated that these microspheres polymerise actin, form actin tails, and are endowed with motility based on the actin in the cellular extracts. In cellular extracts in which the Arp2/3 complex has been eliminated, the microspheres covered with WASP protein no longer have any motility and only possess a residual actin polymerisation activity.

[0015] With regard to N-WASP protein, it has been demonstrated that the C-terminal part of N-WASP, i.e. the C-terminal fragment of 114 amino acids comprising the verprolin homology domain (V region containing the two verprolin homologous sequences), the cofilin homology domain (C region) and the C-terminal acid segment (A region), or VCA fragment, binds to the Arp2/3 complex and strongly stimulates the latter's capacity to nucleate actin polymerisation (Rohatgi et al. 1999, above-mentioned).

[0016] According to recent studies, whole WASP and N-WASP proteins would be required for cellular motility dependent on actin, to the extent that, not only does the C-terminal part of these proteins interact with actin, but also the N-terminal part which keeps the actin filament in the process of formation in proximity to the cellular surface (Loisel et al., Nature, 401: 613-616 (1999); Egile et al., The Journal of Cell Biology, 145: 1319-1332 (1999)).

[0017] The invention follows on from the highlighting by the Inventors of the fact that, contrary to what might be supposed from the prior art described above, fragments of these WASP and N-WASP proteins are sufficient to induce actin polymerisation as this allows the movement of the supports to which said fragments are bound in cellular extracts.

[0018] The invention aims to provide new fragments, or polypeptides derived from WASP and N-WASP proteins, as well as nucleotide sequences coding for these fragments.

[0019] The invention also aims to provide new molecule detection or screening processes having an effect on the formation of the cytoskeleton, in particular cytotoxic molecules or medicaments which can be used within the context of treatment of pathologies linked to abnormal development of the cytoskeleton.

[0020] The invention also aims to provide new reagents and kits for implementation of the above-mentioned processes.

[0021] The invention also concerns the use:

[0022] of peptide fragments of WASP family proteins in eukaryotic cells, in particular in cells of humans or other mammals, or cells of insects or of micro-organisms such as yeasts, said peptide fragments having the property of WASP family proteins to polymerise actin, inducing cellular motility,

[0023] or peptide sequences derived from the above-mentioned peptide fragments of WASP family proteins, in particular by substitution of one or more amino acids of these fragments, said derived sequences having the above-mentioned property of WASP family proteins and said fragments thereof,

[0024] for the preparation of reagents which can be used within the framework of implementation of a process for the detection or screening of molecules having an inhibiting or stimulating effect on the formation of the actin cytoskeleton, and hence an inhibiting or stimulating effect on cellular motility.

[0025] The term “actin polymerisation property inducing cellular motility” above and below means the property of WASP family proteins, or fragments or sequences derived from these, to polymerise actin, inducing the movement of cells of the organism, or of appropriate supports, such as the microspheres described below, in vivo or in vitro.

[0026] The invention also concerns the use of the above-mentioned peptide fragments or derived sequences, within the context of implementation of a process for the detection or screening of molecules capable of being used as medicaments in the treatment of pathologies linked to a dysfunction of the actin polymerisation process within the context of formation of the actin cytoskeleton.

[0027] The invention concerns more particularly the use of above-mentioned peptide fragments or derived sequences, within the context of implementation of a process for the detection or screening of molecules having an inhibiting effect on the formation of the actin cytoskeleton, and thus an inhibiting effect on cellular motility, said molecules being capable of being used:

[0028] as medicaments in the treatment of metastatic cancers,

[0029] or as anti-parasitic antibiotics.

[0030] The invention concerns more particularly the use of above-mentioned peptide fragments or derived sequences, within the context of implementation of a process for the detection of secondary effects of molecules, in particular of medicaments or molecules from the environment, i.e. a process for the detection of molecules capable of having a cytotoxic effect corresponding to inhibition or stimulation of the formation of the actin cytoskeleton.

[0031] The term “WASP family proteins” above and below means the protein produced by the WAS gene, mutated within the context of Wiskott-Aldrich syndrome in humans, as well as proteins which may or may not be of human origin, having at least approx. 45% homology with the above-mentioned human WASP protein, and being involved in the cellular actin polymerisation process, and, possibly, in cellular motility.

[0032] The above-mentioned WASP family proteins also possess the common characteristic of possessing at least three major domains:

[0033] a WH1/Scar domain in the N-terminal part; this domain has structural characteristics similar to a plekstrin homology domain (or pH domain), and is supposed to interact with polymerised actin and with phospholipids,

[0034] a prolin rich domain,

[0035] a WH2/A domain which is divided into three sub-domains, i.e. the above-mentioned verprolin homology sub-domain, cofilin homology sub-domain and acid sub-domain.

[0036] Advantageously, the peptide fragments used within the context of the present invention are chosen from WASP, N-WASP, Scar and Las protein fragments, or peptide sequences derived from the above-mentioned peptide fragments as defined above.

[0037] The invention concerns more particularly the above-mentioned use of peptide fragments chosen from fragments:

[0038] of human or other mammalian WASP protein, in particular bovine or murine WASP protein,

[0039] of human or other mammalian N-WASP protein, in particular bovine or rat N-WASP protein,

[0040] of Scar sub-family proteins, such as Scar1/WAVE protein of Dictyostellium discoideum, or of Caenorhabditis elegans, or of Drosophila melanogaster, of mice or of humans.

[0041] of proteins of the Las sub-family of micro-organisms, in particular yeasts such as the LAS17/Beel protein of Saccharomyces cerevisiae or the WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe.

[0042] Advantageously, the above-mentioned peptide fragments are chosen from those including:

[0043] the verprolin homology domain contained in WASP family proteins, or in a protein derived from these, or at least one of the two verprolin homologous sequences when said WASP family proteins contain two of these sequences, or a peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to bind to actin,

[0044] and the cofilin homology domain contained in WASP family proteins, or in a protein derived from these, or a peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to intervene in actin polymerisation.

[0045] The above-mentioned peptide fragments used within the framework of the present invention possibly also contain the C-terminal acid segment of said WASP proteins or derivatives.

[0046] Advantageously, the above-mentioned peptide fragments do not contain the plekstrin homology domain, and/or the Cdc42 binding domain, and/or the prolin-rich region, defined above, of said WASP family proteins.

[0047] The invention concerns more particularly the above-mentioned use of peptide fragments of WASP family proteins of human origin.

[0048] Advantageously, the peptide fragments of WASP family proteins of human origin used are chosen from fragments of human WASP protein including:

[0049] the verprolin homology domain delimited by the amino acids situated at positions 430 and 446 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined above.

[0050] and the cofilin homology domain delimited by the amino acids situated at positions 469 and 487 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined above.

[0051] Preferably, the above-mentioned fragments of human WASP protein used are chosen from the following:

[0052] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 404 to 430 in FIG. 1, and the C-terminal amino acid corresponds to that situated at one of positions 487 to 502 in FIG. 1,

[0053] the fragment of 99 amino acids delimited by the amino acids situated at positions 404 and 502 in FIG. 1, i.e. the following SEQ ID NO: 4 peptide: Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu Asp Asp Glu Trp Asp Asp

[0054] the fragment of 84 amino acids delimited by the amino acids situated at positions 404 and 487 in FIG. 1, i.e. the following SEQ ID NO: 6 peptide: Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly

[0055] the fragment of 73 amino acids delimited by the amino acids situated at positions 430 and 502 in FIG. 1, i.e. the following SEQ ID NO: 8 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu Asp Asp Glu Trp Asp Asp

[0056] the fragment of 58 amino acids delimited by the amino acids situated at positions 430 and 487 in FIG. 1, i.e. the following SEQ ID NO: 10 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly

[0057] or the peptide sequences derived from the above-mentioned peptide fragments, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the property defined above, of WASP family proteins and said fragments thereof.

[0058] Advantageously, the peptide fragments of WASP family proteins of human origin used are chosen from the fragments of human N-WASP protein including:

[0059] the verprolin homologous sequence delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined above,

[0060] and/or the verprolin homologous sequence delimited by the amino acids situated at positions 433 and 449 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined above,

[0061] and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined above.

[0062] Preferably, the above-mentioned fragments of the human N-WASP protein used are chosen from the following:

[0063] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 392 to 433 in FIG. 2, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 2,

[0064] the fragment of 114 amino acids delimited by the amino acids situated at positions 392 and 505 in FIG. 2, i.e. the following SEQ ID NO: 14 peptide: Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

[0065] the fragment of 97 amino acids delimited by the amino acids situated at positions 392 and 488 in FIG. 2, i.e. the following SEQ ID NO: 16 peptide: Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0066] the fragment of 101 amino acids delimited by the amino acids situated at positions 405 and 505 in FIG. 2, i.e. the following SEQ ID NO: 18 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

[0067] the fragment of 84 amino acids delimited by the amino acids situated at positions 405 and 488 in FIG. 2, i.e. the following SEQ ID NO: 20 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0068] the fragment of 73 amino acids delimited by the amino acids situated at positions 433 and 505 in FIG. 2, i.e. the following SEQ ID NO: 22 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

[0069] the fragment of 56 amino acids delimited by the amino acids situated at positions 433 and 488 in FIG. 2, i.e. the following SEQ ID NO: 24 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0070] or the peptide sequences derived from the above-mentioned peptide fragments, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the property defined above, of WASP family proteins and said fragments thereof.

[0071] Advantageously, the peptide fragments of WASP family proteins of human origin used are chosen from the fragments of human Scar1 protein including:

[0072] the verprolin homology domain delimited by the amino acids situated at positions 497 and 513 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined above,

[0073] and the cofilin homology domain delimited by the amino acids situated at positions 531 and 546 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined above.

[0074] Preferably, the above-mentioned human Scar1 protein fragments used are chosen from the following:

[0075] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 433 to 497 in FIG. 3, and the C-terminal amino acid corresponds to that situated at one of positions 546 to 559 in FIG. 3,

[0076] the fragment of 117 amino acids delimited by the amino acids situated at positions 443 and 559 in FIG. 3, i.e. the following SEQ ID NO: 28 peptide: Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Ile Ala Val Glu Tyr Ser Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Val Asp Trp Leu Glu

[0077] the fragment of 104 amino acids delimited by the amino acids situated at positions 443 and 546 in FIG. 3, i.e. the following SEQ ID NO: 30 peptide: Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser

[0078] the fragment of 63 amino acids delimited by the amino acids situated at positions 497 and 559 in FIG. 3, i.e. the following SEQ ID NO: 32 peptide: Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu

[0079] the fragment of 50 amino acids delimited by the amino acids situated at positions 497 and 546 in FIG. 3, i.e. the following SEQ ID NO: 34 peptide: Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser

[0080] or the peptide sequences derived from the above-mentioned peptide fragments, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the property defined above, of WASP family proteins and said fragments thereof.

[0081] The invention concerns more particularly the above-mentioned use of peptide fragments of WASP family proteins of non-human origin.

[0082] Advantageously, the peptide fragments of WASP family proteins of non-human origin used are chosen from:

[0083] fragments of non-human mammalian WASP family proteins, such as:

[0084] fragments of murine WASP protein, themselves chosen from:

[0085] those including:

[0086] the verprolin homology domain delimited by the amino acids situated at positions 448 and 465 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined above,

[0087] and the cofilin homology domain delimited by the amino acids situated at positions 487 and 505 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined above,

[0088] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 420 to 448 in FIG. 4, and the C-terminal amino acid corresponds to that situated at one of positions 505 to 520 in FIG. 4,

[0089] the fragment of 101 amino acids delimited by the amino acids situated at positions 420 and 520 in FIG. 4, i.e. the following SEQ ID NO: 38 peptide: Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gln Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp Asp Glu Trp Asp Asp

[0090] the fragment of 86 amino acids delimited by the amino acids situated at positions 420 and 505 in FIG. 4, i.e. the following SEQ ID NO: 40 peptide: Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly

[0091] the fragment of 73 amino acids delimited by the amino acids situated at positions 448 and 520 in FIG. 4, i.e. the following SEQ ID NO: 42 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp Asp Glu Trp Asp \ Asp

[0092] the fragment of 58 amino acids delimited by the amino acids situated at positions 448 and 505 in FIG. 4, i.e. the following SEQ ID NO: 44 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly

[0093] fragments of rat N-WASP protein, themselves chosen from:

[0094] those including:

[0095] the verprolin homologous sequence delimited by the amino acids situated at positions 401 and 417 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined above,

[0096] and the verprolin homologous sequence delimited by the amino acids situated at positions 429 and 444 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined above,

[0097] and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 466 and 484 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined above,

[0098] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 401 to 429 in FIG. 5, and the C-terminal amino acid corresponds to that situated at one of positions 484 to 501 in FIG. 5,

[0099] the fragment of 101 amino acids delimited by the amino acids situated at positions 401 and 501 in FIG. 5, i.e. the following SEQ ID NO: 48 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp Asp Glu Trp Glu Asp

[0100] the fragment of 84 amino acids delimited by the amino acids situated at positions 401 and 484 in FIG. 5, i.e. the following SEQ ID NO: 50 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0101] the fragment of 73 amino acids delimited by the amino acids situated at positions 429 and 501 in FIG. 5, i.e. the following SEQ ID NO: 52 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp Asp Glu Trp Glu Asp

[0102] the fragment of 56 amino acids delimited by the amino acids situated at positions 429 and 484 in FIG. 5, i.e. the following SEQ ID NO: 54 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0103] fragments of bovine N-WASP protein, themselves chosen from:

[0104] those including:

[0105] the verprolin homology domain delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined above,

[0106] and/or the verprolin homology domain delimited by the amino acids situated at positions 433 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined above,

[0107] and the cofilin homology domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined above,

[0108] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 405 to 433 in FIG. 6, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 6,

[0109] the fragment of 101 amino acids delimited by the amino acids situated at positions 405 and 505 in FIG. 6, i.e. the following SEQ ID NO: 58 peptide: Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

[0110] the fragment of 84 amino acids delimited by the amino acids situated at positions 405 and 488 in FIG. 6, i.e. the following SEQ ID NO: 60 peptide: Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0111] the fragment of 73 amino acids delimited by the amino acids situated at positions 433 and 488 in FIG. 6, i.e. the following SEQ ID NO: 62 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

[0112] the fragment of 56 amino acids delimited by the amino acids situated at positions 433 and 488 in FIG. 6, i.e. the following SEQ ID NO: 64 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

[0113] fragments of WASP family proteins of micro-organisms, such as:

[0114] fragments of Saccharomyces cerevisiae Las17 protein, themselves chosen from:

[0115] those including:

[0116] the verprolin homology domain delimited by the amino acids situated at positions 447 and 466 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined above,

[0117] and the cofilin homology domain delimited by the amino acids situated at positions 607 and 624 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined above,

[0118] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 422 to 447 in FIG. 7, and the C-terminal amino acid corresponds to that situated at one of positions 624 to 633 in FIG. 7,

[0119] the fragment of 212 amino acids delimited by the amino acids situated at positions 422 and 633 in FIG. 7, i.e. the following SEQ ID NO 68 peptide: Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp Met Asp Asn Gly Asp Asp Trp

[0120] the fragment of 203 amino acids delimited by the amino acids situated at positions 422 and 624 in FIG. 7, i.e. the following SEQ ID NO: 70 peptide: Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His

[0121] the fragment of 187 amino acids delimited by the amino acids situated at positions 447 and 633 in FIG. 7, i.e. the following SEQ ID NO: 72 peptide: Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp Met Asp Asn Gly Asp Asp Trp

[0122] the fragment of 178 amino acids delimited by the amino acids situated at positions 447 and 624 in FIG. 7, i.e. the following SEQ ID NO: 74 peptide: Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His

[0123] fragments of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe, themselves chosen from:

[0124] those including:

[0125] the verprolin homology domain delimited by the amino acids situated at positions 501 and 517 of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined above,

[0126] and the cofilin homology domain delimited by the amino acids situated at positions 548 and 565 of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined above,

[0127] fragments of which the N-terminal amino acid corresponds to that situated at one of positions 477 to 501 in FIG. 8, and the C-terminal amino acid corresponds to that situated at one of positions 565 to 574 in FIG. 8,

[0128] the fragment of 98 amino acids delimited by the amino acids situated at positions 477 and 574 in FIG. 8, i.e. the following SEQ ID NO: 78 peptide: Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp

[0129] the fragment of 89 amino acids delimited by the amino acids situated at positions 477 and 565 in FIG. 8, i.e. the following SEQ ID NO: 80 peptide: Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu

[0130] the fragment of 74 amino acids delimited by the amino acids situated at positions 501 and 574 in FIG. 8, i.e. the following SEQ ID NO: 82 peptide: Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp

[0131] the fragment of 65 amino acids delimited by the amino acids situated at positions 501 and 565 in FIG. 8, i.e. the following SEQ ID NO: 84 peptide: Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu

[0132] the peptide sequences derived from the above-mentioned peptide fragments, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the property defined above, of WASP family proteins and said fragments thereof.

[0133] The invention also concerns the above-mentioned use of above-defined peptide fragments, or sequences derived from these, fused on the N-terminal or C-terminal side with one or more peptide sequences facilitating the detection and purification of the above-mentioned peptide fragments or derived sequences, without greatly affecting the above-mentioned property of the latter to polymerise actin, inducing cellular motility. Among such peptide sequences fused to peptide fragments, or to sequences derived from the latter, of the invention, we may cite that of glutathion-S-transferase (GST, described in Smith D. B. and Johnson K. S., Gene 67: 31-141 (1988)) fused to the N-terminal part of the above-mentioned peptide fragments or derived sequences, or that of epitopes recognised by specific antibodies, such as that of the myc9E10 epitope (described in Evan G. I. et al., Molecular and Cellular Biology 5: 3610-3616 (1985)) fused to the C-terminal part of the above-mentioned peptide fragments or derived sequences.

[0134] The invention also concerns the above-mentioned peptide fragments, or sequences derived from these, as such, i.e. more particularly peptide fragments of WASP family proteins of eukaryotic cells chosen from those including:

[0135] the verprolin homology domain contained in WASP family proteins, or in a protein derived from the latter, or at least one of the two verprolin homologous sequences when said WASP family proteins contain two of these sequences, or one peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to bind to actin,

[0136] and the cofilin homology domain contained in WASP family proteins, or in a protein derived from the latter, or a peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to intervene in actin polymerisation,

[0137] or peptide sequences derived from the above-mentioned peptide fragments of WASP family proteins, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the above-mentioned property of WASP protein and said fragments,

[0138] to the exclusion:

[0139] of the peptide fragment of human WASP protein delimited by the amino acids situated at positions 429 to 503 of the peptide sequence represented in FIG. 1,

[0140] of the peptide fragment of human WASP protein delimited by the amino acids situated at positions 187 to 489 of the peptide sequence represented in FIG. 1,

[0141] of the peptide fragment of human WASP protein delimited by the amino acids situated at positions 422 to 489 of the peptide sequence represented in FIG. 1,

[0142] of the peptide fragment of human N-WASP protein delimited by the amino acids situated at positions 392 to 505 of the peptide sequence represented in FIG. 2,

[0143] of the peptide fragment of human Scar1 protein delimited by the amino acids situated at positions 443 to 559 of the peptide sequence represented in FIG. 3,

[0144] of the peptide fragment of bovine N-WASP protein delimited by the amino acids situated at positions 392 to 505, and that delimited by the amino acids situated at positions 392 to 485 of the peptide sequence represented in FIG. 6.

[0145] The invention concerns more particularly the above-mentioned peptide fragments of human WASP protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0146] the verprolin homology domain delimited by the amino acids situated at positions 430 and 446 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined above,

[0147] and the cofilin homology domain delimited by the amino acids situated at positions 469 and 487 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined above.

[0148] The invention concerns still more particularly fragments of human WASP protein, chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 404 to 430 in FIG. 1, and the C-terminal amino acid corresponds to that situated at one of positions 487 to 502 in FIG. 1, and more particularly the above-mentioned SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10 peptides, or the sequences derived from the latter as defined above.

[0149] The invention concerns more particularly the above-mentioned peptide fragments of human N-WASP protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0150] the verprolin homologous sequence delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined above,

[0151] and/or the verprolin homologous sequence delimited by the amino acids situated at positions 433 and 449 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined above,

[0152] and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined above.

[0153] The invention concerns still more particularly fragments of human N-WASP protein, chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 392 to 433 in FIG. 2, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 2, and more particularly the above-mentioned SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22 and SEQ ID NO: 24 peptides, or the sequences derived from the latter as defined above.

[0154] The invention concerns more particularly the above-mentioned peptide fragments of human Scar1 protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0155] the verprolin homology domain delimited by the amino acids situated at positions 497 and 513 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined above,

[0156] and the cofilin homology domain delimited by the amino acids situated at positions 531 and 546 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined above.

[0157] The invention concerns still more particularly fragments of human Scar1 protein, chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 443 to 497 in FIG. 3, and the C-terminal amino acid corresponds to that situated at one of positions 546 to 559 in FIG. 3, and more particularly the above-mentioned SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32 and SEQ ID NO: 34 peptides, or the sequences derived from the latter as defined above.

[0158] The invention concerns more particularly the above-mentioned peptide fragments of murine WASP protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0159] the verprolin homology domain delimited by the amino acids situated at positions 448 and 465 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined above,

[0160] and the cofilin homology domain delimited by the amino acids situated at positions 487 and 505 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined above.

[0161] The invention concerns still more particularly fragments of murine WASP protein, chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 420 to 448 in FIG. 4, and the C-terminal amino acid corresponds to that situated at one of positions 505 to 520 in FIG. 4, and more particularly the above-mentioned SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42 and SEQ ID NO: 44 peptides, or the sequences derived from the latter as defined above.

[0162] The invention concerns more particularly the above-mentioned peptide fragments of rat N-WASP protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0163] the verprolin homologous sequence delimited by the amino acids situated at positions 401 and 417 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined above,

[0164] and/or the verprolin homologous sequence delimited by the amino acids situated at positions 429 and 444 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined above,

[0165] and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 466 and 484 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined above.

[0166] The invention concerns still more particularly fragments of rat N-WASP protein chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 401 to 429 in FIG. 5, and the C-terminal amino acid corresponds to that situated at one of positions 484 to 501 in FIG. 5, and more particularly the above-mentioned SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52 and SEQ ID NO: 54 peptides, or the sequences derived from the latter as defined above.

[0167] The invention concerns more particularly the above-mentioned peptide fragments of bovine N-WASP protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0168] the verprolin homology domain delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined above,

[0169] and/or the verprolin homology domain delimited by the amino acids situated at positions 433 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined above,

[0170] and the cofilin homology domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined above.

[0171] The invention concerns still more particularly fragments of bovine N-WASP protein chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 405 to 433 in FIG. 6, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 6, and more particularly the above-mentioned SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62 and SEQ ID NO: 64 peptides, or the sequences derived from the latter as defined above.

[0172] The invention concerns more particularly the above-mentioned peptide fragments of Saccharomyces cerevisiae Las17 protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0173] the verprolin homology domain delimited by the amino acids situated at positions 447 and 466 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined above.

[0174] and the cofilin homology domain delimited by the amino acids situated at positions 607 and 624 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined above.

[0175] The invention concerns still more particularly fragments of Saccharomyces cerevisiae Las17 protein chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 422 to 447 in FIG. 7, and the C-terminal amino acid corresponds to that situated at one of positions 624 to 633 in FIG. 7, and more particularly the above-mentioned SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72 and SEQ ID NO: 74 peptides, or the sequences derived from the latter as defined above.

[0176] The invention concerns more particularly the above-mentioned peptide fragments of Schizosaccharomyces pombe (Wsp1p) protein, or peptide sequences derived from the latter, said fragments being chosen from those including:

[0177] the verprolin homology domain delimited by the amino acids situated at positions 501 and 517 of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined above,

[0178] and the cofilin homology domain delimited by the amino acids situated at positions 548 and 565 of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined above.

[0179] The invention concerns still more particularly fragments of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe chosen from fragments of which the N-terminal amino acid corresponds to that situated at one of positions 477 to 501 in FIG. 8, and the C-terminal amino acid corresponds to that situated at one of positions 565 to 574 in FIG. 8, and more particularly the above-mentioned SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82 and SEQ ID NO: 84 peptides, or the sequences derived from the latter as defined above.

[0180] The invention also concerns the nucleotide sequences coding for the above-mentioned peptide fragments, or for the proteins derived from the latter, or for the fusion proteins as described above.

[0181] The invention concerns more particularly:

[0182] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1244 to 1322 of the nucleotide sequence SEQ ID NO: 1 represented in FIG. 1, and the 3′ end corresponds to the nucleotide situated at one of positions 1495 to 1540 in FIG. 1, said nucleotide sequences coding for the above-mentioned fragments of human WASP protein, of which the N-terminal amino acid corresponds to that situated at one of positions 404 to 430 in FIG. 1, and the C-terminal amino acid corresponds to that situated at one of positions 487 to 502 in FIG. 1,

[0183] nucleotide sequence SEQ ID NO: 3 delimited by the nucleotides situated at positions 1244 and 1540 of FIG. 1, and coding for the peptide fragment of human WASP protein corresponding to the above-mentioned SEQ ID NO: 4 peptide,

[0184] nucleotide sequence SEQ ID NO: 5 delimited by the nucleotides situated at positions 1244 and 1495 of FIG. 1, and coding for the peptide fragment of human WASP protein corresponding to the above-mentioned SEQ ID NO: 6 peptide,

[0185] nucleotide sequence SEQ ID NO: 7 delimited by the nucleotides situated at positions 1322 and 1540 of FIG. 1, and coding for the peptide fragment of human WASP protein corresponding to the above-mentioned SEQ ID NO: 8 peptide,

[0186] nucleotide sequence SEQ ID NO: 9 delimited by the nucleotides situated at positions 1322 and 1495 of FIG. 1, and coding for the peptide fragment of human WASP protein corresponding to the above-mentioned SEQ ID NO: 10 peptide,

[0187] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0188] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0189] The invention concerns still more particularly:

[0190] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1174 to 1299 of the nucleotide sequence SEQ ID NO: 11 represented in FIG. 2, and the 3′ end corresponds to the nucleotide situated at one of positions 1464 to 1515 in FIG. 2, said nucleotide sequences coding for the above-mentioned fragments of N-WASP protein, of which the N-terminal amino acid corresponds to that situated at one of positions 392 to 433 in FIG. 2 and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 2, to the exclusion of the nucleotide sequence delimited by the nucleotides situated at positions 1174 to 1515 coding for the peptide fragment of N-WASP protein delimited by the amino acids situated at positions 392 to 505 of the peptide sequence represented in FIG. 2,

[0191] nucleotide sequence SEQ ID NO: 15 delimited by the nucleotides situated at positions 1174 and 1464 coding for the peptide fragment of N-WASP protein corresponding to the above-mentioned SEQ ID NO: 16 peptide, nucleotide sequence SEQ ID NO: 17 delimited by the nucleotides situated at positions 1213 and 1515 coding for the peptide fragment of N-WASP protein corresponding to the above-mentioned SEQ ID NO: 18 peptide,

[0192] nucleotide sequence SEQ ID NO: 19 delimited by the nucleotides situated at positions 1213 and 1464 coding for the peptide fragment of N-WASP protein corresponding to the above-mentioned SEQ ID NO: 20 peptide,

[0193] nucleotide sequence SEQ ID NO: 21 delimited by the nucleotides situated at positions 1297 and 1515 coding for the peptide fragment of N-WASP protein corresponding to the above-mentioned SEQ ID NO: 22 peptide,

[0194] nucleotide sequence SEQ ID NO: 23 delimited by the nucleotides situated at positions 1297 and 1464 coding for the peptide fragment of N-WASP protein corresponding to the above-mentioned SEQ ID NO: 24 peptide,

[0195] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0196] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0197] The invention concerns still more particularly:

[0198] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1327 to 1489 of the nucleotide sequence SEQ ID NO: 26 represented in FIG. 3, and the 3′ end corresponds to the nucleotide situated at one of positions 1638 to 1677 in FIG. 3, said nucleotide sequences coding for the above-mentioned fragments of human Scar1 protein, of which the N-terminal amino acid corresponds to that situated at one of positions 546 to 497 in FIG. 3 and the C-terminal amino acid corresponds to that situated at one of positions 487 to 559 in FIG. 3,

[0199] nucleotide sequence SEQ ID NO: 27 delimited by the nucleotides situated at positions 1327 and 1677 in FIG. 3, and coding for the peptide fragment of human Scar1 protein corresponding to the above-mentioned SEQ ID NO: 28 peptide,

[0200] nucleotide sequence SEQ ID NO: 29 delimited by the nucleotides situated at positions 1327 and 1638 in FIG. 3, and coding for the peptide fragment of human Scar1 protein corresponding to the above-mentioned SEQ ID NO: 30 peptide,

[0201] nucleotide sequence SEQ ID NO: 31 delimited by the nucleotides situated at positions 1489 and 1677 in FIG. 3, and coding for the peptide fragment of human Scar1 protein corresponding to the above-mentioned SEQ ID NO: 32 peptide,

[0202] nucleotide sequence SEQ ID NO: 33 delimited by the nucleotides situated at positions 1489 and 1638 in FIG. 3, and coding for the peptide fragment of human Scar1 protein corresponding to the above-mentioned SEQ ID NO: 34 peptide,

[0203] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0204] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0205] The invention concerns still more particularly:

[0206] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1282 to 1366 of the nucleotide sequence SEQ ID NO: 36 represented in FIG. 4, and the 3′ end corresponds to the nucleotide situated at one of positions 1539 to 1584 in FIG. 4, said nucleotide sequences coding for the above-mentioned fragments of murine WASP protein, of which the N-terminal amino acid corresponds to that situated at one of positions 420 to 448 in FIG. 4 and the C-terminal amino acid corresponds to that situated at one of positions 505 to 520 in FIG. 4,

[0207] nucleotide sequence SEQ ID NO: 37 delimited by the nucleotides situated at positions 1282 and 1584 in FIG. 4, and coding for the peptide fragment of murine WASP protein corresponding to the above-mentioned SEQ ID NO: 38 peptide,

[0208] nucleotide sequence SEQ ID NO: 39 delimited by the nucleotides situated at positions 1282 and 1584 in FIG. 4, and coding for the peptide fragment of murine WASP protein corresponding to the above-mentioned SEQ ID NO: 40 peptide,

[0209] nucleotide sequence SEQ ID NO: 41 delimited by the nucleotides situated at positions 1366 and 1584 in FIG. 4, and coding for the peptide fragment of murine WASP protein corresponding to the above-mentioned SEQ ID NO: 42 peptide,

[0210] nucleotide sequence SEQ ID NO: 43 delimited by the nucleotides situated at positions 1366 and 1539 in FIG. 4, and coding for the peptide fragment of murine WASP protein corresponding to the above-mentioned SEQ ID NO: 44 peptide,

[0211] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0212] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0213] The invention concerns still more particularly:

[0214] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1272 to 1356 of the nucleotide sequence SEQ ID NO: 46 represented in FIG. 5, and the 3′ end corresponds to the nucleotide situated at one of positions 1523 to 1574 in FIG. 5, said nucleotide sequences coding for the above-mentioned fragments of rat N-WASP protein, of which the N-terminal amino acid corresponds to that situated at one of positions 401 to 429 in FIG. 5 and the C-terminal amino acid corresponds to that situated at one of positions 484 to 501 in FIG. 5,

[0215] nucleotide sequence SEQ ID NO: 47 delimited by the nucleotides situated at positions 1272 and 1574 in FIG. 5, and coding for the peptide fragment of rat N-WASP protein corresponding to the above-mentioned SEQ ID NO: 48 peptide,

[0216] nucleotide sequence SEQ ID NO: 49 delimited by the nucleotides situated at positions 1272 and 1523 in FIG. 5, and coding for the peptide fragment of rat N-WASP protein corresponding to the above-mentioned SEQ ID NO: 50 peptide,

[0217] nucleotide sequence SEQ ID NO: 51 delimited by the nucleotides situated at positions 1356 and 1574 in FIG. 5, and coding for the peptide fragment of rat N-WASP protein corresponding to the above-mentioned SEQ ID NO: 52 peptide,

[0218] nucleotide sequence SEQ ID NO: 53 delimited by the nucleotides situated at positions 1356 and 1523 in FIG. 5, and coding for the peptide fragment of rat N-WASP protein corresponding to the above-mentioned SEQ ID NO: 54 peptide,

[0219] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0220] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0221] The invention concerns still more particularly:

[0222] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1500 to 1584 of the nucleotide sequence SEQ ID NO: 56 represented in FIG. 6, and the 3′ end corresponds to the nucleotide situated at one of positions 1751 to 1802 in FIG. 6, said nucleotide sequences coding for the above-mentioned fragments of bovine N-WASP protein, of which the N-terminal amino acid corresponds to that situated at one of positions 405 to 433 in FIG. 6 and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 6,

[0223] nucleotide sequence SEQ ID NO: 57 delimited by the nucleotides situated at positions 1500 and 1802 in FIG. 6, and coding for the peptide fragment of bovine N-WASP protein corresponding to the above-mentioned SEQ ID NO: 58 peptide,

[0224] nucleotide sequence SEQ ID NO: 59 delimited by the nucleotides situated at positions 1500 and 1751 in FIG. 6, and coding for the peptide fragment of bovine N-WASP protein corresponding to the above-mentioned SEQ ID NO: 60 peptide,

[0225] nucleotide sequence SEQ ID NO: 61 delimited by the nucleotides situated at positions 1584 and 1802 in FIG. 6, and coding for the peptide fragment of bovine N-WASP protein corresponding to the above-mentioned SEQ ID NO: 62 peptide,

[0226] nucleotide sequence SEQ ID NO: 63 delimited by the nucleotides situated at positions 1584 and 1751 in FIG. 6, and coding for the peptide fragment of bovine N-WASP protein corresponding to the above-mentioned SEQ ID NO: 64 peptide,

[0227] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0228] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0229] The invention concerns still more particularly:

[0230] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 2035 to 2110 of the nucleotide sequence SEQ ID NO: 66 represented in FIG. 7, and the 3′ end corresponds to the nucleotide situated at one of positions 2643 to 2670 in FIG. 7, said nucleotide sequences coding for the above-mentioned fragments of Saccharomyces cerevisiae Las17 protein, of which the N-terminal amino acid corresponds to that situated at one of positions 422 to 447 in FIG. 7 and the C-terminal amino acid corresponds to that situated at one of positions 624 to 633 in FIG. 7,

[0231] nucleotide sequence SEQ ID NO: 67 delimited by the nucleotides situated at positions 2035 and 2670 in FIG. 7, and coding for the peptide fragment of Saccharomyces cerevisiae Las17 protein corresponding to the above-mentioned SEQ ID NO: 68 peptide,

[0232] nucleotide sequence SEQ ID NO: 69 delimited by the nucleotides situated at positions 2035 and 2643 in FIG. 7, and coding for the peptide fragment of Saccharomyces cerevisiae Las 17 protein corresponding to the above-mentioned SEQ ID NO: 70 peptide,

[0233] nucleotide sequence SEQ ID NO: 71 delimited by the nucleotides situated at positions 2110 and 2670 in FIG. 7, and coding for the peptide fragment of Saccharomyces cerevisiae Las17 protein corresponding to the above-mentioned SEQ ID NO: 72 peptide,

[0234] nucleotide sequence SEQ ID NO: 73 delimited by the nucleotides situated at positions 2110 and 2643 in FIG. 7, and coding for the peptide fragment of Saccharomyces cerevisiae Las17 protein corresponding to the above-mentioned SEQ ID NO: 74 peptide,

[0235] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0236] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0237] The invention concerns still more particularly:

[0238] the nucleotide sequences of which the 5′ end corresponds to the nucleotide situated at one of positions 1429 to 1501 of the nucleotide sequence SEQ ID NO: 76 represented in FIG. 8, and the 3′ end corresponds to the nucleotide situated at one of positions 1695 to 1722 in FIG. 8, said nucleotide sequences coding for the above-mentioned fragments of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe, of which the N-terminal amino acid corresponds to that situated at one of positions 477 to 501 in FIG. 8 and the C-terminal amino acid corresponds to that situated at one of positions 565 to 574 in FIG. 8,

[0239] nucleotide sequence SEQ ID NO: 77 delimited by the nucleotides situated at positions 1429 and 1722 in FIG. 8, and coding for the peptide fragment of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe corresponding to the above-mentioned SEQ ID NO: 78 peptide,

[0240] nucleotide sequence SEQ ID NO: 79 delimited by the nucleotides situated at positions 1429 and 1695 in FIG. 8, and coding for the peptide fragment of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe corresponding to the above-mentioned SEQ ID NO: 80 peptide,

[0241] nucleotide sequence SEQ ID NO: 81 delimited by the nucleotides situated at positions 1501 and 1722 in FIG. 8, and coding for the peptide fragment of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe corresponding to the above-mentioned SEQ ID NO: 82 peptide,

[0242] nucleotide sequence SEQ ID NO: 83 delimited by the nucleotides situated at positions 1501 and 1695 in FIG. 8, and coding for the peptide fragment of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe corresponding to the above-mentioned SEQ ID NO: 84 peptide,

[0243] the nucleotide sequences derived by degeneration of the genetic code of the above-mentioned nucleotide sequences, and coding for the above-mentioned peptide fragments,

[0244] the nucleotide sequences derived from the above-mentioned nucleotide sequences and coding for the sequences derived from said peptide fragments as defined above.

[0245] The invention also concerns vectors, in particular plasmids, containing a nucleotide sequence as defined above.

[0246] The invention also concerns host cells transformed by an above-mentioned vector, said cells expressing the above-mentioned peptide fragments, or the derived sequences described above, in recombinant form. Advantageously, the above-mentioned host cells are chosen from the following: Escherichia coli D5α and Escherichia coli BL21.

[0247] The invention also concerns reagents for the implementation of a process for the detection or screening of molecules having an inhibiting or stimulating effect on the formation of the actin cytoskeleton, and hence an inhibiting or stimulating effect on cellular motility, said reagent comprising at least one peptide fragment defined above, bound or adsorbed to a support capable of moving under the effect of actin polymerisation, when said support bound to said fragment is placed in a medium containing the elements necessary for actin polymerisation, in particular when said support is added to a medium containing mainly Arp2/3 complex, VASP protein (vasodilator-stimulated phosphoprotein), colifin, and capping proteins, this medium possibly being, for example, an extract prepared from supernatants of lysed cells from the organism.

[0248] Capping protein is an element essential for WASP-dependent motility. These proteins are capable of converting actin polymerisation into actin-dependent movement, spatially limiting polymerisation to certain sites in the cellular cytoskeleton. By comparison, in the absence of capping proteins, actin polymerisation still takes place, but since it is uncontrolled, it cannot generate any force. Capping proteins are made up of two sub-units, alpha (p34) and beta (p32) which are both required for capping activity. The dimer is associated with the plus end of the filament which is normally favoured for the addition of actin monomers and thus blocks the addition of monomers. Genes coding for capping proteins have been identified in all species studied to date, and have been shown to be indispensable for the survival of organisms. In humans, Cap beta 1, beta2, G and CapZ have been identified to date. It is also known that multifunctional proteins such as gelsolin and villin also have a capping activity in addition to their other actin-modifying activities.

[0249] The invention concerns more particularly reagents as defined above, chosen from microspheres whose diameter is advantageously between approx. 100 nm and approx. 10,000 nm, the material constituting the microspheres itself being chosen preferably from polystyrenes or latex, said microspheres each advantageously containing approx. 5,000 to approx. 50,000 molecules of above-mentioned peptide fragment or a sequence derived according to the invention.

[0250] Advantageously, the above-mentioned peptide fragment, or its derived sequence, are adsorbed onto the surface of said microspheres, said reagent being obtained by simple mixing of said microspheres with said peptide fragment, or with its derived sequence.

[0251] The invention concerns more particularly reagents as defined above, chosen from drops of oil, in particular oil of C14 to C18, such as palmitic acid, whose diameter is advantageously between approx. 1 μm and approx. 20 μm.

[0252] The invention also concerns any process for the detection or screening of molecules as defined above, having an inhibiting or stimulating effect on the formation of the actin cytoskeleton, and hence an inhibiting or stimulating effect on cellular motility, said process comprising:

[0253] a stage of placing the tested molecule in the presence of a reagent as described above, into a medium containing actin and the elements necessary for actin polymerisation, in particular into an extract of cellular supernatant or other medium as defined above,

[0254] followed by the eventual detection of inhibition or activation of the actin polymerisation process on the surface of said reagent, compared with a control (i.e. a medium as described above not containing the tested molecule, and containing said reagent), respectively demonstrating an inhibiting or stimulating effect on the formation of the actin cytoskeleton.

[0255] Advantageously, the above-mentioned medium into which the tested molecule is placed in the presence of said reagent, contains a compound marked in particular by fluorescence, making it possible to detect movement of said reagent. By way of illustration, the above-mentioned marked compound is a fluorescent derivative of actin, such as actin-rhodamine (available commercially), enabling actin polymerisation to be made visible by epifluorescence microscopy.

[0256] The invention also concerns the use of the process as defined above, for detection or screening of molecules, as defined above, capable of being used as medicaments in the treatment of pathologies linked to a dysfunction of the actin polymerisation process within the context of formation of the actin cytoskeleton, or capable of having a cytotoxic effect corresponding to inhibition or stimulation of the formation of the actin cytoskeleton.

[0257] The invention also concerns a kit for implementation of an above-mentioned process, comprising

[0258] a reagent as defined above,

[0259] possibly a marked compound defined above enabling polymerisation of actin to be made visible, in particular actin marked with fluorescence,

[0260] possibly an appropriate medium containing the elements necessary for actin polymerisation, in particular an extract of cellular supernatant as defined above.

[0261] The invention will be further illustrated by means of the following detailed description of preparation of microspheres coated with a peptide fragment of the invention, and of detection of actin polymerisation on the surface of these microspheres in an extract of cellular supernatant.

[0262] I) Material and Methods

[0263] The sequence coding for the WH2/A domain of human WASP protein (i.e. the fragment of 99 amino acids delimited by the amino acids situated at positions 404 and 502 in FIG. 1, also designated peptide SEQ ID NO: 4) and that coding for the myc9E10 epitope were amplified by PCR. The myc epitope fused to the carboxy-terminal portion of the protein serves as a molecular tag, making possible the detection of the protein by immunological approaches without needing an anti-WASP antibody. This DNA sequence was introduced into the pGEX2T vector (Pharmacia) downstream of the sequence coding for glutathion-S-transferase (GST), generating the WH2/A-pGEX2T plasmid. The GST domain was chosen in this work, as it facilitates purification of the recombinant protein, and it has been shown that this domain does not inhibit the actin-polymerisation capacity of the GST-VCA protein derived from N-WASP in a pyrene-actin test (Rohatgi et al., 1999). FIG. 3 shows the organisation into domains of GST-WH2. This recombinant protein is made up of GST and WH2/A domains, of 237 and 99 residues and of a myc9E10 epitope of 9 residues, respectively.

[0264] Purification and characterisation of the GST-WH2/A protein were carried out as follows.

[0265]E. coli bacteria (strain BL21) were transformed with WH2/1-pGEX2T plasmid. The bacteria were cultivated in standard LB medium containing the antibiotic ampicillin to keep bacteria comprising the plasmid under selection pressure. The bacteria were cultivated in suspension at 37° C. until the culture reached an optical density of 0.8 to 600 nm. Subsequently, isopropylthio-β-D-galactoside (IPTG) was added to the medium, with a final concentration of 1 mM to induce production of the protein. After 2 hours, the bacteria were collected by centrifugation, and the pellets were stored at −80° C. The pellets were thawed and added to extraction buffer (saline solution buffered with phosphate pH 7.2, 200 NaCl, 2 mM EDTA (ethylenediaminetetraacetic acid)) containing 1 μg/ml of each of the following protease inhibitors: leupeptin, benzamidin, pepstatin, in a ratio of 1 gr of pellet to 10 volumes of extraction buffer. The suspension was sonicated until it was no longer viscous. The extract was centrifuged at 20,000×g for 10 minutes at 4° C. and the supernatant containing the GST-WH2/A protein was conserved. The GST-WH2/A protein was purified from the bacterial extract by affinity chromatography on resin coupled to glutathione (Pharmacia) and eluated with 20 mM glutathione reduced according to the manufacturers' recommendations. The purification was confirmed by analysis of the GST-WH2/A by electrophoresis on acrylamide gel. The presence of the myc epitope in the GST-WH2/A sequence was confirmed by immunological impression with an antibody directed against this epitope.

[0266] The GST-WH2/A protein was absorbed onto 500 nm latex beads (Polyscience Inc., 400 Valley Road, Warrington Pa., USA) following the manufacturers' instructions. These beads, added to the extracts prepared from cells, are capable of polymerising actin sufficiently to bring about the movement of these beads.

[0267] Adsorption of the GST-WA protein onto drops of oil: a water-oil emulsion was prepared as follows: 100 μl of oil are mixed with 900 μl of borate buffer 0.1 MpH=8.5 (boric acid buffered with NaOH). The solution is sonicated (wave) for a few seconds and a white foam is obtained. The size of the oil drops is between 20 μm and 1 μm. In a 1.5 ml Eppendorf, 20 μl of this solution are mixed with 100 μl of the above-mentioned GST-WH2/A protein (also designated GST-WA) (1 mg/ml in borate buffer). This solution is left to incubate at ambient temperature for 12 hours (overnight) on a rotating agitator. After incubation, the solution is centrifuged for approx. one minute at 5000 rpm with a small table-top centrifuge. Drops of oil are located in the upper part of the solution. A too strong and/or too prolonged centrifugation brings about fusion of the oil drops. The bottom part of the solution (buffer alone) is removed with a pipette and the top part of the solution is resuspended in PBS (Phosphate Buffer Saline). The oil drops are cleaned at least four times in this manner and finally resuspended in 100 μl of PBS. 1 μl of this solution is mixed with 10 μl of HeLa extracts.

[0268] Inhibition of actin polymerisation induced by GST-WA protein: 10 μm polystyrene particles (Polysciences inc.) are covered to saturation with GST-WA protein according to the manufacturer's protocol. The particles are resuspended to 1% solid in PBS (Phosphate Buffer Saline) and stored on ice. To test the independence of the actin polymerisation mechanism induced by GST-WA we prepared three solutions. Each sample contained 15 μl of HeLa extracts (supplemented with ATP, creatine phosphate and actin marked with rhodamine), 0.5 μl of GST-WA particles and 1.5 μl of PBS (A), or 1.5 μl of GST-WA protein at 1 mg/ml (B) or 1.5 μl of GST-PRO protein (PRO corresponding to the fragment delimited by the amino acids situated at positions 235 to 584 of the ActA protein of Listeria monocytogenes) at 1 mg/ml (C). 6 μl of the final mixture of these three solutions were sealed between slide and coverglass. We observed fluorescence (rhodamine actin) around the particles for thirty minutes and measured the intensity of fluorescence on a population of forty beads using a microscope (Leica) and a linear digital camera (Micromax Princeton instrument). The average intensity M (arbitrary unit) was 95,000±13,000 for sample A (positive control). For sample B, M=0±1000, the actin polymerisation on the surface of the particles was inhibited by the addition of GST-WA in solution. For sample C, M=4000±1500; the addition to the solution of the GST-PRO protein did not inhibit the actin polymerisation on the surface of the particles. The intensity was lower than in case A (PBS); this is probably due to the activity induced by GST-PRO in the extracts which results in a very high consumption of rhodamine actin. These results show that the actin polymerisation mechanism induced by the GST-WA protein is independent of the GST-PRO actin polymerisation mechanism.

[0269] B) Uses

[0270] 1) Uses of GST-WH2/A Beads and of the Cellular Actin Polymerisation Test

[0271] Cellular movement dependent on the actin cytoskeleton occurs during embryonic development, immune response and healing of wounds. However, the molecular mechanism whereby the cytoskeleton participates in physiological or physio-pathological processes are still poorly understood. This is due to the fact that few in vitro experimental systems are available for studying these processes.

[0272] The invention proposes an in vitro test for actin polymerisation on the surface of beads, and shows that the system reproduces the essential characteristics of actin polymerisation in human cells. For example, these beads recruit large proteins for actin polymerisation in cells, such as Arp2/3 complex and cofilin. Moreover, the components recruited onto the surface of the beads, are targets for tyrosine kinase signalling pathways. Thanks to this in vitro system, it is now possible to study the conditions necessary for actin polymerisation in cells, a process which up to now has not been accessible to direct experimental manipulation.

[0273] a) Anti-Metastatic Component Screening Process

[0274] At present, it has not been possible to develop anti-metastatic medicaments targeted at the actin cytoskeleton, as simple tests for screening banks of chemicals have not been available. The beads of the invention “mimic” the dynamic cytoskeleton of cells in motion and thus constitute an ideal test for researching molecules affecting the dynamics of the cytoskeleton. Chemicals thus identified will subsequently be used to develop medicaments for treatment of metastatic cancers.

[0275] b) Anti-Parasitic Antibiotic Screening Process

[0276] The system of beads described here is based on human proteins which are necessary for actin polymerisation in human cells. However, these proteins have been conserved throughout evolution, from yeast to humans, via amoebae. Despite the conservation of their basic function, these proteins also diverge at the level of their primary sequence, suggesting particular functional differences. As in the case of metastatic cancers, the actin cytoskeleton of parasites is rarely the target of medicaments used in the treatment of parasitoses, despite the important role which it plays in the infectious cycle of numerous parasites (for example amoebae). It is conceivable that medicaments which affect the human actin cytoskeleton only when they are used in a strong concentration, affect that of parasites at much lower concentrations. This is why, thanks to the universal nature of the evolution of the actin cytoskeleton, the system of beads of the invention also enables research into medicaments which can be used in the treatment of parasitoses.

[0277] c) Detection of Secondary Effects of Medicaments

[0278] In another test, the beads are used to verify and confirm that medicaments have no secondary effects on cellular actin polymerisation. Thus it is possible to avoid the disastrous consequences of drug treatments unintentionally affecting cellular migration during the development of the embryo in pregnant women. For example after some years of use, it has been shown that the teratogenic properties of valproic acid, an anti-epileptic medicament, are due to its secondary effects on the actin cytoskeleton.

[0279] 2) Process for Screening Molecules Affecting Cellular Actin Polymerisation

[0280] The most effective screening tests carried out on new medicaments have the following properties: they are simple, cheap and quick. The cellular actin polymerisation test of the invention has all these characteristics. Beads measuring 200-500 nm can be produced by absorbing purified GST-WH2/A recombinant protein on their surface. Once prepared, the beads are stable for several months at 4° C. The beads are then added to extracts prepared from supernatants of lysed cells in culture. The volume of extract necessary for an experiment is of the order of a few microlitres, reducing the cost of the experiment. These extracts have the advantage that they can be produced in a large quantity and stored for a long period, at −80° C. Before the addition of these beads, a fluorescent actin derivative (commercial actin-rhodamine) is added to the extract to make the actin polymerisation visible by epifluorescence microscopy. The actin polymerisation is observed 15 min after the addition of the beads, resulting in an accumulation of fluorescent actin around the beads. Starting with a stock of standardised reagents, the experiment takes less than 30 min and one person is capable of dealing with several samples in parallel. This process can be automated, enabling the rapid screening of a large number samples.

[0281] To identify the active components, it is necessary to test the chemical products at variable concentrations. The inventors have shown that low quantities of solvents used to dissolve these products (water, ethanol, dimethyl sulphoxide) do not disturb the system of the invention. Moreover, this screening test has been validated by showing that it is sensitive to known medicaments inhibiting actin polymerisation, such as latrunculin and cytochalasin D.

1 84 1 1806 DNA Homo sapiens CDS (35)..(1540) 1 agcctcgcca gagaagacaa gggcagaaag cacc atg agt ggg ggc cca atg gga 55 Met Ser Gly Gly Pro Met Gly 1 5 gga agg ccc ggg ggc cga gga gca cca gcg gtt cag cag aac ata ccc 103 Gly Arg Pro Gly Gly Arg Gly Ala Pro Ala Val Gln Gln Asn Ile Pro 10 15 20 tcc acc ctc ctc cag gac cac gag aac cag cga ctc ttt gag atg ctt 151 Ser Thr Leu Leu Gln Asp His Glu Asn Gln Arg Leu Phe Glu Met Leu 25 30 35 gga cga aaa tgc ttg acg ctg gcc act gca gtt gtt cag ctg tac ctg 199 Gly Arg Lys Cys Leu Thr Leu Ala Thr Ala Val Val Gln Leu Tyr Leu 40 45 50 55 gcg ctg ccc cct gga gct gag cac tgg acc aag gag cat tgt ggg gct 247 Ala Leu Pro Pro Gly Ala Glu His Trp Thr Lys Glu His Cys Gly Ala 60 65 70 gtg tgc ttc gtg aag gat aac ccc cag aag tcc tac ttc atc cgc ctt 295 Val Cys Phe Val Lys Asp Asn Pro Gln Lys Ser Tyr Phe Ile Arg Leu 75 80 85 tac ggc ctt cag gct ggt cgg ctg ctc tgg gaa cag gag ctg tac tca 343 Tyr Gly Leu Gln Ala Gly Arg Leu Leu Trp Glu Gln Glu Leu Tyr Ser 90 95 100 cag ctt gtc tac tcc acc ccc acc ccc ttc ttc cac acc ttc gct gga 391 Gln Leu Val Tyr Ser Thr Pro Thr Pro Phe Phe His Thr Phe Ala Gly 105 110 115 gat gac tgc caa gcg ggg ctg aac ttt gca gac gag gac gag gcc cag 439 Asp Asp Cys Gln Ala Gly Leu Asn Phe Ala Asp Glu Asp Glu Ala Gln 120 125 130 135 gcc ttc cgg gcc ctc gtg cag gag aag ata caa aaa agg aat cag agg 487 Ala Phe Arg Ala Leu Val Gln Glu Lys Ile Gln Lys Arg Asn Gln Arg 140 145 150 caa agt gga gac aga cgc cag cta ccc cca cca cca aca cca gcc aat 535 Gln Ser Gly Asp Arg Arg Gln Leu Pro Pro Pro Pro Thr Pro Ala Asn 155 160 165 gaa gag aga aga gga ggg ctc cca ccc ctg ccc ctg cat cca ggt gga 583 Glu Glu Arg Arg Gly Gly Leu Pro Pro Leu Pro Leu His Pro Gly Gly 170 175 180 gac caa gga ggc cct cca gtg ggt ccg ctc tcc ctg ggg ctg gcg aca 631 Asp Gln Gly Gly Pro Pro Val Gly Pro Leu Ser Leu Gly Leu Ala Thr 185 190 195 gtg gac atc cag aac cct gac atc acg agt tca cga tac cgt ggg ctc 679 Val Asp Ile Gln Asn Pro Asp Ile Thr Ser Ser Arg Tyr Arg Gly Leu 200 205 210 215 cca gca cct gga cct agc cca gct gat aag aaa cgc tca ggg aag aag 727 Pro Ala Pro Gly Pro Ser Pro Ala Asp Lys Lys Arg Ser Gly Lys Lys 220 225 230 aag atc agc aaa gct gat att ggt gca ccc agt gga ttc aag cat gtc 775 Lys Ile Ser Lys Ala Asp Ile Gly Ala Pro Ser Gly Phe Lys His Val 235 240 245 agc cac gtg ggg tgg gac ccc cag aat gga ttt gac gtg aac aac ctc 823 Ser His Val Gly Trp Asp Pro Gln Asn Gly Phe Asp Val Asn Asn Leu 250 255 260 gac cca gat ctg cgg agt ctg ttc tcc agg gca gga atc agc gag gcc 871 Asp Pro Asp Leu Arg Ser Leu Phe Ser Arg Ala Gly Ile Ser Glu Ala 265 270 275 cag ctc acc gac gcc gag acc tct aaa ctt atc tac gac ttc att gag 919 Gln Leu Thr Asp Ala Glu Thr Ser Lys Leu Ile Tyr Asp Phe Ile Glu 280 285 290 295 gac cag ggt ggg ctg gag gct gtg cgg cag gag atg agg cgc cag gag 967 Asp Gln Gly Gly Leu Glu Ala Val Arg Gln Glu Met Arg Arg Gln Glu 300 305 310 cca ctt ccg ccg ccc cca ccg cca tct cga gga ggg aac cag ctc ccc 1015 Pro Leu Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Asn Gln Leu Pro 315 320 325 cgg ccc cct att gtg ggg ggt aac aag ggt cgt tct ggt cca ctg ccc 1063 Arg Pro Pro Ile Val Gly Gly Asn Lys Gly Arg Ser Gly Pro Leu Pro 330 335 340 cct gta cct ttg ggg att gcc cca ccc cca cca aca ccc cgg gga ccc 1111 Pro Val Pro Leu Gly Ile Ala Pro Pro Pro Pro Thr Pro Arg Gly Pro 345 350 355 cca ccc cca ggc cga ggg ggc cct cca cca cca ccc cct cca gct act 1159 Pro Pro Pro Gly Arg Gly Gly Pro Pro Pro Pro Pro Pro Pro Ala Thr 360 365 370 375 gga cgt tct gga cca ctg ccc cct cca ccc cct gga gct ggt ggg cca 1207 Gly Arg Ser Gly Pro Leu Pro Pro Pro Pro Pro Gly Ala Gly Gly Pro 380 385 390 ccc atg cca cca cca ccg cca cca ccg cca ccg ccg ccc agc tcc ggg 1255 Pro Met Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Ser Ser Gly 395 400 405 aat gga cca gcc cct ccc cca ctc cct cct gct ctg gtg cct gcc ggg 1303 Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu Val Pro Ala Gly 410 415 420 ggc ctg gcc cct ggt ggg ggt cgg gga gcg ctt ttg gat caa atc cgg 1351 Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg 425 430 435 cag gga att cag ctg aac aag acc cct ggg gcc cca gag agc tca gcg 1399 Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala 440 445 450 455 ctg cag cca cca cct cag agc tca gag gga ctg gtg ggg gcc ctg atg 1447 Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met 460 465 470 cac gtg atg cag aag aga agc aga gcc atc cac tcc tcc gac gaa ggg 1495 His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly 475 480 485 gag gac cag gct ggc gat gaa gat gaa gat gat gaa tgg gat gac 1540 Glu Asp Gln Ala Gly Asp Glu Asp Glu Asp Asp Glu Trp Asp Asp 490 495 500 tgagtggctg agttacttgc tgccctgtgc tcctccccgc aggacatggc tccccctcca 1600 cctgctctgt gcccaccctc cactctcctc ttccagggcc cccaaccccc catttcttcc 1660 ccaccaaccc ctccaatgct gttatccctg cctggtcctc acactcaccc aacaatccca 1720 aggccctttt tatacaaaaa ttctcagttc tcttcactca aggattttta aagaaaaata 1780 aagaattgt ctttctgtct ctctat 1806 2 502 PRT Homo sapiens 2 Met Ser Gly Gly Pro Met Gly Gly Arg Pro Gly Gly Arg Gly Ala Pro 1 5 10 15 Ala Val Gln Gln Asn Ile Pro Ser Thr Leu Leu Gln Asp His Glu Asn 20 25 30 Gln Arg Leu Phe Glu Met Leu Gly Arg Lys Cys Leu Thr Leu Ala Thr 35 40 45 Ala Val Val Gln Leu Tyr Leu Ala Leu Pro Pro Gly Ala Glu His Trp 50 55 60 Thr Lys Glu His Cys Gly Ala Val Cys Phe Val Lys Asp Asn Pro Gln 65 70 75 80 Lys Ser Tyr Phe Ile Arg Leu Tyr Gly Leu Gln Ala Gly Arg Leu Leu 85 90 95 Trp Glu Gln Glu Leu Tyr Ser Gln Leu Val Tyr Ser Thr Pro Thr Pro 100 105 110 Phe Phe His Thr Phe Ala Gly Asp Asp Cys Gln Ala Gly Leu Asn Phe 115 120 125 Ala Asp Glu Asp Glu Ala Gln Ala Phe Arg Ala Leu Val Gln Glu Lys 130 135 140 Ile Gln Lys Arg Asn Gln Arg Gln Ser Gly Asp Arg Arg Gln Leu Pro 145 150 155 160 Pro Pro Pro Thr Pro Ala Asn Glu Glu Arg Arg Gly Gly Leu Pro Pro 165 170 175 Leu Pro Leu His Pro Gly Gly Asp Gln Gly Gly Pro Pro Val Gly Pro 180 185 190 Leu Ser Leu Gly Leu Ala Thr Val Asp Ile Gln Asn Pro Asp Ile Thr 195 200 205 Ser Ser Arg Tyr Arg Gly Leu Pro Ala Pro Gly Pro Ser Pro Ala Asp 210 215 220 Lys Lys Arg Ser Gly Lys Lys Lys Ile Ser Lys Ala Asp Ile Gly Ala 225 230 235 240 Pro Ser Gly Phe Lys His Val Ser His Val Gly Trp Asp Pro Gln Asn 245 250 255 Gly Phe Asp Val Asn Asn Leu Asp Pro Asp Leu Arg Ser Leu Phe Ser 260 265 270 Arg Ala Gly Ile Ser Glu Ala Gln Leu Thr Asp Ala Glu Thr Ser Lys 275 280 285 Leu Ile Tyr Asp Phe Ile Glu Asp Gln Gly Gly Leu Glu Ala Val Arg 290 295 300 Gln Glu Met Arg Arg Gln Glu Pro Leu Pro Pro Pro Pro Pro Pro Ser 305 310 315 320 Arg Gly Gly Asn Gln Leu Pro Arg Pro Pro Ile Val Gly Gly Asn Lys 325 330 335 Gly Arg Ser Gly Pro Leu Pro Pro Val Pro Leu Gly Ile Ala Pro Pro 340 345 350 Pro Pro Thr Pro Arg Gly Pro Pro Pro Pro Gly Arg Gly Gly Pro Pro 355 360 365 Pro Pro Pro Pro Pro Ala Thr Gly Arg Ser Gly Pro Leu Pro Pro Pro 370 375 380 Pro Pro Gly Ala Gly Gly Pro Pro Met Pro Pro Pro Pro Pro Pro Pro 385 390 395 400 Pro Pro Pro Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro 405 410 415 Pro Ala Leu Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly 420 425 430 Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro 435 440 445 Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu 450 455 460 Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala 465 470 475 480 Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu 485 490 495 Asp Asp Glu Trp Asp Asp 500 3 297 DNA Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 3 ccc agc tcc ggg aat gga cca gcc cct ccc cca ctc cct cct gct ctg 48 Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu 1 5 10 15 gtg cct gcc ggg ggc ctg gcc cct ggt ggg ggt cgg gga gcg ctt ttg 96 Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu 20 25 30 gat caa atc cgg cag gga att cag ctg aac aag acc cct ggg gcc cca 144 Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro 35 40 45 gag agc tca gcg ctg cag cca cca cct cag agc tca gag gga ctg gtg 192 Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val 50 55 60 ggg gcc ctg atg cac gtg atg cag aag aga agc aga gcc atc cac tcc 240 Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser 65 70 75 80 tcc gac gaa ggg gag gac cag gct ggc gat gaa gat gaa gat gat gaa 288 Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu Asp Asp Glu 85 90 95 tgg gat gac 297 Trp Asp Asp 4 99 PRT Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 4 Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu 1 5 10 15 Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu 20 25 30 Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro 35 40 45 Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val 50 55 60 Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser 65 70 75 80 Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu Asp Asp Glu 85 90 95 Trp Asp Asp 5 252 DNA Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 5 ccc agc tcc ggg aat gga cca gcc cct ccc cca ctc cct cct gct ctg 48 Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu 1 5 10 15 gtg cct gcc ggg ggc ctg gcc cct ggt ggg ggt cgg gga gcg ctt ttg 96 Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu 20 25 30 gat caa atc cgg cag gga att cag ctg aac aag acc cct ggg gcc cca 144 Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro 35 40 45 gag agc tca gcg ctg cag cca cca cct cag agc tca gag gga ctg gtg 192 Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val 50 55 60 ggg gcc ctg atg cac gtg atg cag aag aga agc aga gcc atc cac tcc 240 Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser 65 70 75 80 tcc gac gaa ggg 252 Ser Asp Glu Gly 6 84 PRT Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 6 Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu 1 5 10 15 Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu 20 25 30 Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro 35 40 45 Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val 50 55 60 Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser 65 70 75 80 Ser Asp Glu Gly 7 219 DNA Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 7 ggt cgg gga gcg ctt ttg gat caa atc cgg cag gga att cag ctg aac 48 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 aag acc cct ggg gcc cca gag agc tca gcg ctg cag cca cca cct cag 96 Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln 20 25 30 agc tca gag gga ctg gtg ggg gcc ctg atg cac gtg atg cag aag aga 144 Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 agc aga gcc atc cac tcc tcc gac gaa ggg gag gac cag gct ggc gat 192 Ser Arg Ala Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp 50 55 60 gaa gat gaa gat gat gaa tgg gat gac 219 Glu Asp Glu Asp Asp Glu Trp Asp Asp 65 70 8 73 PRT Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 8 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln 20 25 30 Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 Ser Arg Ala Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp 50 55 60 Glu Asp Glu Asp Asp Glu Trp Asp Asp 65 70 9 174 DNA Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 9 ggt cgg gga gcg ctt ttg gat caa atc cgg cag gga att cag ctg aac 48 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 aag acc cct ggg gcc cca gag agc tca gcg ctg cag cca cca cct cag 96 Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln 20 25 30 agc tca gag gga ctg gtg ggg gcc ctg atg cac gtg atg cag aag aga 144 Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 agc aga gcc atc cac tcc tcc gac gaa ggg 174 Ser Arg Ala Ile His Ser Ser Asp Glu Gly 50 55 10 58 PRT Artificial sequence Description of the artificial sequence Fragment of the human WASP protein 10 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln 20 25 30 Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 Ser Arg Ala Ile His Ser Ser Asp Glu Gly 50 55 11 1518 DNA Homosapiens CDS (1)..(1518) 11 atg agc tcc gtc cag cag cag ccg ccg ccg ccg cgg agg gtc acc aac 48 Met Ser Ser Val Gln Gln Gln Pro Pro Pro Pro Arg Arg Val Thr Asn 1 5 10 15 gtg ggg tcc ctg ttg ctc acc ccg cag gag aac gag tcc ctc ttc act 96 Val Gly Ser Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Thr 20 25 30 ttc ctc ggc aag aaa tgt gtg act atg tct tca gca gtg gtg cag tta 144 Phe Leu Gly Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu 35 40 45 tat gca gca gat cgg aac tgt atg tgg tca aag aag tgc agt ggt gtt 192 Tyr Ala Ala Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val 50 55 60 12 505 PRT Homo sapiens 12 Met Ser Ser Val Gln Gln Gln Pro Pro Pro Pro Arg Arg Val Thr Asn 1 5 10 15 Val Gly Ser Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Thr 20 25 30 Phe Leu Gly Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu 35 40 45 Tyr Ala Ala Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val 50 55 60 Ala Cys Leu Val Lys Asp Asn Pro Gln Arg Ser His Phe Leu Arg Ile 65 70 75 80 Phe Asp Ile Lys Asp Gly Lys Leu Leu Trp Glu Gln Glu Leu Tyr Asn 85 90 95 Asn Phe Val Tyr Asn Ser Pro Arg Gly Tyr Phe His Thr Phe Ala Gly 100 105 110 Asp Thr Cys Gln Val Ala Leu Asn Phe Ala Asn Glu Glu Glu Ala Lys 115 120 125 Lys Phe Arg Lys Ala Val Thr Asp Leu Leu Gly Arg Arg Gln Arg Lys 130 135 140 Ser Glu Lys Arg Arg Asp Pro Pro Asn Gly Pro Asn Leu Pro Met Ala 145 150 155 160 Thr Val Asp Ile Lys Asn Pro Glu Ile Thr Thr Asn Arg Phe Tyr Gly 165 170 175 Pro Gln Val Asn Asn Ile Ser His Thr Lys Glu Lys Lys Lys Gly Lys 180 185 190 Ala Lys Lys Lys Arg Leu Thr Lys Gly Asp Ile Gly Thr Pro Ser Asn 195 200 205 Phe Gln His Ile Gly His Val Gly Trp Asp Pro Asn Thr Gly Ser Asp 210 215 220 Leu Asn Asn Leu Asp Pro Glu Leu Lys Asn Leu Phe Asp Met Cys Gly 225 230 235 240 Ile Leu Glu Ala Gln Leu Lys Glu Arg Glu Thr Leu Lys Val Ile Tyr 245 250 255 Asp Phe Ile Glu Lys Thr Gly Gly Val Glu Ala Val Lys Asn Glu Leu 260 265 270 Arg Arg Gln Ala Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Pro Pro 275 280 285 Pro Pro Pro Pro Pro Pro His Ser Ser Gly Pro Pro Pro Pro Pro Ala 290 295 300 Arg Gly Arg Gly Ala Pro Pro Pro Pro Pro Ser Arg Ala Pro Thr Ala 305 310 315 320 Ala Pro Pro Pro Pro Pro Pro Ser Arg Pro Ser Val Glu Val Pro Pro 325 330 335 Pro Pro Pro Asn Arg Met Tyr Pro Pro Pro Pro Pro Ala Leu Pro Ser 340 345 350 Ser Ala Pro Ser Gly Pro Pro Pro Pro Pro Pro Ser Val Leu Gly Val 355 360 365 Gly Pro Val Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly 370 375 380 Pro Pro Pro Pro Pro Gly Leu Pro Ser Asp Gly Asp His Gln Val Pro 385 390 395 400 Thr Thr Ala Gly Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly 405 410 415 Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser 420 425 430 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 435 440 445 Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 450 455 460 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 465 470 475 480 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp 485 490 495 Phe Glu Asp Asp Asp Glu Trp Glu Asp 500 505 13 342 DNA Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 13 cct tct gat ggg gac cat cag gtt cca act act gca gga aac aaa gca 48 Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala 1 5 10 15 gct ctt tta gat caa att aga gag ggt gct cag cta aaa aaa gtg gag 96 Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu 20 25 30 cag aac agt cgg cca gtg tcc tgc tct gga cga gat gca ctg tta gac 144 Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp 35 40 45 cag ata cga cag ggt atc caa cta aaa tct gtg gct gat ggc caa gag 192 Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu 50 55 60 tct aca cca cca aca cct gca ccc act tca gga att gtg ggt gca tta 240 Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu 65 70 75 80 atg gaa gtg atg cag aaa agg agc aaa gcc att cat tct tca gat gaa 288 Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu 85 90 95 gat gaa gat gaa gat gat gaa gaa gat ttt gag gat gat gat gag tgg 336 Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp 100 105 110 gaa gac 342 Glu Asp 14 114 PRT Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 14 Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala 1 5 10 15 Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu 20 25 30 Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp 35 40 45 Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu 50 55 60 Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu 65 70 75 80 Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu 85 90 95 Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp 100 105 110 Glu Asp 15 291 DNA Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 15 cct tct gat ggg gac cat cag gtt cca act act gca gga aac aaa gca 48 Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala 1 5 10 15 gct ctt tta gat caa att aga gag ggt gct cag cta aaa aaa gtg gag 96 Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu 20 25 30 cag aac agt cgg cca gtg tcc tgc tct gga cga gat gca ctg tta gac 144 Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp 35 40 45 cag ata cga cag ggt atc caa cta aaa tct gtg gct gat ggc caa gag 192 Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu 50 55 60 tct aca cca cca aca cct gca ccc act tca gga att gtg ggt gca tta 240 Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu 65 70 75 80 atg gaa gtg atg cag aaa agg agc aaa gcc att cat tct tca gat gaa 288 Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu 85 90 95 gat 291 Asp 16 97 PRT Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 16 Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala 1 5 10 15 Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu 20 25 30 Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp 35 40 45 Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu 50 55 60 Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu 65 70 75 80 Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu 85 90 95 Asp 17 303 DNA Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 17 aac aaa gca gct ctt tta gat caa att aga gag ggt gct cag cta aaa 48 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 aaa gtg gag cag aac agt cgg cca gtg tcc tgc tct gga cga gat gca 96 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 ctg tta gac cag ata cga cag ggt atc caa cta aaa tct gtg gct gat 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp 35 40 45 ggc caa gag tct aca cca cca aca cct gca ccc act tca gga att gtg 192 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 ggt gca tta atg gaa gtg atg cag aaa agg agc aaa gcc att cat tct 240 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 tca gat gaa gat gaa gat gaa gat gat gaa gaa gat ttt gag gat gat 288 Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp 85 90 95 gat gag tgg gaa gac 303 Asp Glu Trp Glu Asp 100 18 101 PRT Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 18 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp 35 40 45 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp 85 90 95 Asp Glu Trp Glu Asp 100 19 252 DNA Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 19 aac aaa gca gct ctt tta gat caa att aga gag ggt gct cag cta aaa 48 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 aaa gtg gag cag aac agt cgg cca gtg tcc tgc tct gga cga gat gca 96 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 ctg tta gac cag ata cga cag ggt atc caa cta aaa tct gtg gct gat 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp 35 40 45 ggc caa gag tct aca cca cca aca cct gca ccc act tca gga att gtg 192 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 ggt gca tta atg gaa gtg atg cag aaa agg agc aaa gcc att cat tct 240 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 tca gat gaa gat 252 Ser Asp Glu Asp 20 84 PRT Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 20 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp 35 40 45 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 Ser Asp Glu Asp 21 219 DNA Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 21 gga cga gat gca ctg tta gac cag ata cga cag ggt atc caa cta aaa 48 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 tct gtg gct gat ggc caa gag tct aca cca cca aca cct gca ccc act 96 Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 tca gga att gtg ggt gca tta atg gaa gtg atg cag aaa agg agc aaa 144 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 gcc att cat tct tca gat gaa gat gaa gat gaa gat gat gaa gaa gat 192 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp 50 55 60 ttt gag gat gat gat gag tgg gaa gac 219 Phe Glu Asp Asp Asp Glu Trp Glu Asp 65 70 22 73 PRT Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 22 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp 50 55 60 Phe Glu Asp Asp Asp Glu Trp Glu Asp 65 70 23 168 DNA Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 23 gga cga gat gca ctg tta gac cag ata cga cag ggt atc caa cta aaa 48 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 tct gtg gct gat ggc caa gag tct aca cca cca aca cct gca ccc act 96 Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 tca gga att gtg ggt gca tta atg gaa gtg atg cag aaa agg agc aaa 144 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 gcc att cat tct tca gat gaa gat 168 Ala Ile His Ser Ser Asp Glu Asp 50 55 24 56 PRT Artificial sequence Description of the artificial sequence Fragment of the human N-WASP protein 24 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 Ala Ile His Ser Ser Asp Glu Asp 50 55 25 1758 DNA Homo sapiens CDS (1)..(1677) 25 atg ccg cta gtg aaa aga aac atc gat cct agg cac ttg tgc cac aca 48 Met Pro Leu Val Lys Arg Asn Ile Asp Pro Arg His Leu Cys His Thr 1 5 10 15 gca ctg cct aga ggc att aag aat gaa ctg gaa tgt gta acc aat att 96 Ala Leu Pro Arg Gly Ile Lys Asn Glu Leu Glu Cys Val Thr Asn Ile 20 25 30 tcc ttg gca aat ata att aga caa cta agt agc cta agt aaa tat gct 144 Ser Leu Ala Asn Ile Ile Arg Gln Leu Ser Ser Leu Ser Lys Tyr Ala 35 40 45 gaa gat ata ttt gga gaa tta ttc aat gaa gca cat agt ttt tcc ttc 192 Glu Asp Ile Phe Gly Glu Leu Phe Asn Glu Ala His Ser Phe Ser Phe 50 55 60 aga gtc aac tca ttg caa gaa cgt gtg gac cgt tta tct gtt agt gtt 240 Arg Val Asn Ser Leu Gln Glu Arg Val Asp Arg Leu Ser Val Ser Val 65 70 75 80 aca cag ctt gat cca aag gaa gaa gaa ttg tct ttg caa gat ata aca 288 Thr Gln Leu Asp Pro Lys Glu Glu Glu Leu Ser Leu Gln Asp Ile Thr 85 90 95 atg agg aaa gct ttc cga agt tct aca att caa gac cag cag ctt ttc 336 Met Arg Lys Ala Phe Arg Ser Ser Thr Ile Gln Asp Gln Gln Leu Phe 100 105 110 gat cgc aag act ttg cct att cca tta cag gag acg tac gat gtt tgt 384 Asp Arg Lys Thr Leu Pro Ile Pro Leu Gln Glu Thr Tyr Asp Val Cys 115 120 125 gaa cag cct cca cct ctc aat ata ctc act cct tat aga gat gat ggt 432 Glu Gln Pro Pro Pro Leu Asn Ile Leu Thr Pro Tyr Arg Asp Asp Gly 130 135 140 aaa gaa ggt ctg aag ttt tat acc aat cct tcg tat ttc ttt gat cta 480 Lys Glu Gly Leu Lys Phe Tyr Thr Asn Pro Ser Tyr Phe Phe Asp Leu 145 150 155 160 tgg aaa gaa aaa atg ttg caa gat aca gag gat aag agg aag gaa aag 528 Trp Lys Glu Lys Met Leu Gln Asp Thr Glu Asp Lys Arg Lys Glu Lys 165 170 175 agg aag cag aag cag aaa aat cta gat cgt cct cat gaa cca gaa aaa 576 Arg Lys Gln Lys Gln Lys Asn Leu Asp Arg Pro His Glu Pro Glu Lys 180 185 190 gtg cca aga gca cct cat gac agg cgg cga gaa tgg cag aag ctg gcc 624 Val Pro Arg Ala Pro His Asp Arg Arg Arg Glu Trp Gln Lys Leu Ala 195 200 205 caa ggt cca gag ctg gct gaa gat gat gct aat ctc tta cat aag cat 672 Gln Gly Pro Glu Leu Ala Glu Asp Asp Ala Asn Leu Leu His Lys His 210 215 220 att gaa gtt gct aat ggc cca gcc tct cat ttt gaa aca aga cct cag 720 Ile Glu Val Ala Asn Gly Pro Ala Ser His Phe Glu Thr Arg Pro Gln 225 230 235 240 aca tac gtg gat cat atg gat gga tct tac tca ctt tct gcc ttg cca 768 Thr Tyr Val Asp His Met Asp Gly Ser Tyr Ser Leu Ser Ala Leu Pro 245 250 255 ttt agt cag atg agt gag ctt ctg act aga gct gag gaa agg gta tta 816 Phe Ser Gln Met Ser Glu Leu Leu Thr Arg Ala Glu Glu Arg Val Leu 260 265 270 gtc aga cca cat gaa cca cct cca cct cca cca atg cat gga gca gga 864 Val Arg Pro His Glu Pro Pro Pro Pro Pro Pro Met His Gly Ala Gly 275 280 285 gat gca aaa ccg ata ccc acc tgt atc agt tct gct aca ggt ttg ata 912 Asp Ala Lys Pro Ile Pro Thr Cys Ile Ser Ser Ala Thr Gly Leu Ile 290 295 300 gaa aat cgc cct cag tca cca gct aca ggc aga aca cct gtg ttt gtg 960 Glu Asn Arg Pro Gln Ser Pro Ala Thr Gly Arg Thr Pro Val Phe Val 305 310 315 320 agc ccc act ccc cca cct cct cca cca cct ctt cca tct gcc ttg tca 1008 Ser Pro Thr Pro Pro Pro Pro Pro Pro Pro Leu Pro Ser Ala Leu Ser 325 330 335 act tcc tca tta aga gct tca atg act tca act cct ccc cct cca gta 1056 Thr Ser Ser Leu Arg Ala Ser Met Thr Ser Thr Pro Pro Pro Pro Val 340 345 350 cct ccc cca cct cca cct cca gcc act gct ttg caa gct cca gca gta 1104 Pro Pro Pro Pro Pro Pro Pro Ala Thr Ala Leu Gln Ala Pro Ala Val 355 360 365 cca cca cct cca gct cct ctt cag att gcc cct gga gtt ctt cac cca 1152 Pro Pro Pro Pro Ala Pro Leu Gln Ile Ala Pro Gly Val Leu His Pro 370 375 380 gct cct cct cca att gca cct cct cta gta cag ccc tct cca cca gta 1200 Ala Pro Pro Pro Ile Ala Pro Pro Leu Val Gln Pro Ser Pro Pro Val 385 390 395 400 gct aga gct gcc cca gta tgt gag act gta cca gtt cat cca ctc cca 1248 Ala Arg Ala Ala Pro Val Cys Glu Thr Val Pro Val His Pro Leu Pro 405 410 415 caa ggt gaa gtt cag ggg ctg cct cca ccc cca cca ccg cct cct ctg 1296 Gln Gly Glu Val Gln Gly Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu 420 425 430 cct cca cct ggc att cga cca tca tca cct gtc aca gtt aca gct ctt 1344 Pro Pro Pro Gly Ile Arg Pro Ser Ser Pro Val Thr Val Thr Ala Leu 435 440 445 gct cat cct ccc tct ggg cta cat cca act cca tct act gcc cca ggt 1392 Ala His Pro Pro Ser Gly Leu His Pro Thr Pro Ser Thr Ala Pro Gly 450 455 460 ccc cat gtt cca tta atg cct cca tct cct cca tca caa gtt ata cct 1440 Pro His Val Pro Leu Met Pro Pro Ser Pro Pro Ser Gln Val Ile Pro 465 470 475 480 gct tct gag cca aag cgc cat cca tca acc cta cct gta atc agt gat 1488 Ala Ser Glu Pro Lys Arg His Pro Ser Thr Leu Pro Val Ile Ser Asp 485 490 495 gcc agg agt gtg cta ctg gaa gca ata cga aaa ggt att cag cta cgc 1536 Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg 500 505 510 aaa gta gaa gag cag cgt gaa cag gaa gct aag cat gaa cgc att gaa 1584 Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu 515 520 525 aac gat gtt gcc acc atc ctg tct cgc cgt att gct gtt gaa tat agt 1632 Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser 530 535 540 gat tcg gaa gat gat tca gaa ttt gat gaa gta gat tgg ttg gag 1677 Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu 545 550 555 taagaaaaat gcattgataa atattacaaa actgaatgca aatgtccttt gtggtgcttg 1737 ttccttgaaa atgtttggtc a 1758 26 559 PRT Homo sapiens 26 Met Pro Leu Val Lys Arg Asn Ile Asp Pro Arg His Leu Cys His Thr 1 5 10 15 Ala Leu Pro Arg Gly Ile Lys Asn Glu Leu Glu Cys Val Thr Asn Ile 20 25 30 Ser Leu Ala Asn Ile Ile Arg Gln Leu Ser Ser Leu Ser Lys Tyr Ala 35 40 45 Glu Asp Ile Phe Gly Glu Leu Phe Asn Glu Ala His Ser Phe Ser Phe 50 55 60 Arg Val Asn Ser Leu Gln Glu Arg Val Asp Arg Leu Ser Val Ser Val 65 70 75 80 Thr Gln Leu Asp Pro Lys Glu Glu Glu Leu Ser Leu Gln Asp Ile Thr 85 90 95 Met Arg Lys Ala Phe Arg Ser Ser Thr Ile Gln Asp Gln Gln Leu Phe 100 105 110 Asp Arg Lys Thr Leu Pro Ile Pro Leu Gln Glu Thr Tyr Asp Val Cys 115 120 125 Glu Gln Pro Pro Pro Leu Asn Ile Leu Thr Pro Tyr Arg Asp Asp Gly 130 135 140 Lys Glu Gly Leu Lys Phe Tyr Thr Asn Pro Ser Tyr Phe Phe Asp Leu 145 150 155 160 Trp Lys Glu Lys Met Leu Gln Asp Thr Glu Asp Lys Arg Lys Glu Lys 165 170 175 Arg Lys Gln Lys Gln Lys Asn Leu Asp Arg Pro His Glu Pro Glu Lys 180 185 190 Val Pro Arg Ala Pro His Asp Arg Arg Arg Glu Trp Gln Lys Leu Ala 195 200 205 Gln Gly Pro Glu Leu Ala Glu Asp Asp Ala Asn Leu Leu His Lys His 210 215 220 Ile Glu Val Ala Asn Gly Pro Ala Ser His Phe Glu Thr Arg Pro Gln 225 230 235 240 Thr Tyr Val Asp His Met Asp Gly Ser Tyr Ser Leu Ser Ala Leu Pro 245 250 255 Phe Ser Gln Met Ser Glu Leu Leu Thr Arg Ala Glu Glu Arg Val Leu 260 265 270 Val Arg Pro His Glu Pro Pro Pro Pro Pro Pro Met His Gly Ala Gly 275 280 285 Asp Ala Lys Pro Ile Pro Thr Cys Ile Ser Ser Ala Thr Gly Leu Ile 290 295 300 Glu Asn Arg Pro Gln Ser Pro Ala Thr Gly Arg Thr Pro Val Phe Val 305 310 315 320 Ser Pro Thr Pro Pro Pro Pro Pro Pro Pro Leu Pro Ser Ala Leu Ser 325 330 335 Thr Ser Ser Leu Arg Ala Ser Met Thr Ser Thr Pro Pro Pro Pro Val 340 345 350 Pro Pro Pro Pro Pro Pro Pro Ala Thr Ala Leu Gln Ala Pro Ala Val 355 360 365 Pro Pro Pro Pro Ala Pro Leu Gln Ile Ala Pro Gly Val Leu His Pro 370 375 380 Ala Pro Pro Pro Ile Ala Pro Pro Leu Val Gln Pro Ser Pro Pro Val 385 390 395 400 Ala Arg Ala Ala Pro Val Cys Glu Thr Val Pro Val His Pro Leu Pro 405 410 415 Gln Gly Glu Val Gln Gly Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu 420 425 430 Pro Pro Pro Gly Ile Arg Pro Ser Ser Pro Val Thr Val Thr Ala Leu 435 440 445 Ala His Pro Pro Ser Gly Leu His Pro Thr Pro Ser Thr Ala Pro Gly 450 455 460 Pro His Val Pro Leu Met Pro Pro Ser Pro Pro Ser Gln Val Ile Pro 465 470 475 480 Ala Ser Glu Pro Lys Arg His Pro Ser Thr Leu Pro Val Ile Ser Asp 485 490 495 Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg 500 505 510 Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu 515 520 525 Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser 530 535 540 Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu 545 550 555 27 351 DNA Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 27 gtc aca gtt aca gct ctt gct cat cct ccc tct ggg cta cat cca act 48 Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr 1 5 10 15 cca tct act gcc cca ggt ccc cat gtt cca tta atg cct cca tct cct 96 Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro 20 25 30 cca tca caa gtt ata cct gct tct gag cca aag cgc cat cca tca acc 144 Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr 35 40 45 cta cct gta atc agt gat gcc agg agt gtg cta ctg gaa gca ata cga 192 Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg 50 55 60 aaa ggt att cag cta cgc aaa gta gaa gag cag cgt gaa cag gaa gct 240 Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala 65 70 75 80 aag cat gaa cgc att gaa aac gat gtt gcc acc atc ctg tct cgc cgt 288 Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg 85 90 95 att gct gtt gaa tat agt gat tcg gaa gat gat tca gaa ttt gat gaa 336 Ile Ala Val Glu Tyr Ser Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu 100 105 110 gta gat tgg ttg gag 351 Val Asp Trp Leu Glu 115 28 117 PRT Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 28 Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr 1 5 10 15 Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro 20 25 30 Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr 35 40 45 Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg 50 55 60 Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala 65 70 75 80 Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg 85 90 95 Ile Ala Val Glu Tyr Ser Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu 100 105 110 Val Asp Trp Leu Glu 115 29 312 DNA Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 29 gtc aca gtt aca gct ctt gct cat cct ccc tct ggg cta cat cca act 48 Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr 1 5 10 15 cca tct act gcc cca ggt ccc cat gtt cca tta atg cct cca tct cct 96 Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro 20 25 30 cca tca caa gtt ata cct gct tct gag cca aag cgc cat cca tca acc 144 Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr 35 40 45 cta cct gta atc agt gat gcc agg agt gtg cta ctg gaa gca ata cga 192 Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg 50 55 60 aaa ggt att cag cta cgc aaa gta gaa gag cag cgt gaa cag gaa gct 240 Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala 65 70 75 80 aag cat gaa cgc att gaa aac gat gtt gcc acc atc ctg tct cgc cgt 288 Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg 85 90 95 att gct gtt gaa tat agt gat tcg 312 Ile Ala Val Glu Tyr Ser Asp Ser 100 30 104 PRT Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 30 Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr 1 5 10 15 Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro 20 25 30 Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr 35 40 45 Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg 50 55 60 Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala 65 70 75 80 Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg 85 90 95 Ile Ala Val Glu Tyr Ser Asp Ser 100 31 189 DNA Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 31 gcc agg agt gtg cta ctg gaa gca ata cga aaa ggt att cag cta cgc 48 Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg 1 5 10 15 aaa gta gaa gag cag cgt gaa cag gaa gct aag cat gaa cgc att gaa 96 Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu 20 25 30 aac gat gtt gcc acc atc ctg tct cgc cgt att gct gtt gaa tat agt 144 Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser 35 40 45 gat tcg gaa gat gat tca gaa ttt gat gaa gta gat tgg ttg gag 189 Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu 50 55 60 32 63 PRT Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 32 Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg 1 5 10 15 Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu 20 25 30 Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser 35 40 45 Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu 50 55 60 33 150 DNA Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 33 gcc agg agt gtg cta ctg gaa gca ata cga aaa ggt att cag cta cgc 48 Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg 1 5 10 15 aaa gta gaa gag cag cgt gaa cag gaa gct aag cat gaa cgc att gaa 96 Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu 20 25 30 aac gat gtt gcc acc atc ctg tct cgc cgt att gct gtt gaa tat agt 144 Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser 35 40 45 gat tcg 150 Asp Ser 50 34 50 PRT Artificial sequence Description of the artificial sequence Fragment of the human Scar1 protein 34 Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg 1 5 10 15 Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu 20 25 30 Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser 35 40 45 Asp Ser 50 35 2069 DNA Mus musculus CDS (25)..(1584) 35 agcaggacta aggcagaagg cagc atg aat agt ggc cct ggc cct gta gga 51 Met Asn Ser Gly Pro Gly Pro Val Gly 1 5 ggc agg cct ggg gga cga ggg gga cca gcc gtt cag cag aac att cct 99 Gly Arg Pro Gly Gly Arg Gly Gly Pro Ala Val Gln Gln Asn Ile Pro 10 15 20 25 tcc aac ctc ctc cag gac cat gaa aac cag aga ctc ttt gag ctt ctt 147 Ser Asn Leu Leu Gln Asp His Glu Asn Gln Arg Leu Phe Glu Leu Leu 30 35 40 ggc cga aaa tgc tgg aca ctg gct acc aca gtt gtt cag ctc tac ctg 195 Gly Arg Lys Cys Trp Thr Leu Ala Thr Thr Val Val Gln Leu Tyr Leu 45 50 55 gca ctg ccc cct gga gct gag cac tgg acc atg gaa cac tgc ggg gct 243 Ala Leu Pro Pro Gly Ala Glu His Trp Thr Met Glu His Cys Gly Ala 60 65 70 gtg tgc ttc gtg aag gat aac cct cag aag tcc tac ttc atc cgc ctt 291 Val Cys Phe Val Lys Asp Asn Pro Gln Lys Ser Tyr Phe Ile Arg Leu 75 80 85 tat gcg cta cag gct ggt cgg cta ctc tgg gaa cag gag ctg tac tct 339 Tyr Ala Leu Gln Ala Gly Arg Leu Leu Trp Glu Gln Glu Leu Tyr Ser 90 95 100 105 cag ctg gtt tat ctc act ccc acc ccg ttc ttc cac act ttt gct gga 387 Gln Leu Val Tyr Leu Thr Pro Thr Pro Phe Phe His Thr Phe Ala Gly 110 115 120 gat gac tgt caa gta gga ctg aac ttt gcg gat gag agt gaa gcc cag 435 Asp Asp Cys Gln Val Gly Leu Asn Phe Ala Asp Glu Ser Glu Ala Gln 125 130 135 gcc ttc cgg gcc ttg gtg cag gag aag ata caa aaa agg aat cag agg 483 Ala Phe Arg Ala Leu Val Gln Glu Lys Ile Gln Lys Arg Asn Gln Arg 140 145 150 caa agc gga gaa aga cgc cag cta cca cca cca cca gca cca atc aat 531 Gln Ser Gly Glu Arg Arg Gln Leu Pro Pro Pro Pro Ala Pro Ile Asn 155 160 165 gag gag aga aga gga ggg ctc cca cct gtg ccc cca cac ccg ggt gga 579 Glu Glu Arg Arg Gly Gly Leu Pro Pro Val Pro Pro His Pro Gly Gly 170 175 180 185 gat cat ggg ggc cca tca ggt ggt cca cta tct cta gga ctt gtg acg 627 Asp His Gly Gly Pro Ser Gly Gly Pro Leu Ser Leu Gly Leu Val Thr 190 195 200 gtc gac att cag aac cct gac atc aca agt tca cga tac cgt ggg ctc 675 Val Asp Ile Gln Asn Pro Asp Ile Thr Ser Ser Arg Tyr Arg Gly Leu 205 210 215 cct gca cct ggc cct ggc cca act gat aag aaa cgc tca ggg aaa aag 723 Pro Ala Pro Gly Pro Gly Pro Thr Asp Lys Lys Arg Ser Gly Lys Lys 220 225 230 aag atc agc aaa gct gat atc gga gca ccg agt gga ttc aaa cat gtc 771 Lys Ile Ser Lys Ala Asp Ile Gly Ala Pro Ser Gly Phe Lys His Val 235 240 245 agc cac gtg ggc tgg gat ccc cag aat gga ttt gat gtg aac aac cta 819 Ser His Val Gly Trp Asp Pro Gln Asn Gly Phe Asp Val Asn Asn Leu 250 255 260 265 gac ccg gat ctg cgg agc ttg ttc tcc agg gca gga atc agc gag gcc 867 Asp Pro Asp Leu Arg Ser Leu Phe Ser Arg Ala Gly Ile Ser Glu Ala 270 275 280 cag ctc act gac gca gag acc tcc aag ctc atc tac gat ttt att gag 915 Gln Leu Thr Asp Ala Glu Thr Ser Lys Leu Ile Tyr Asp Phe Ile Glu 285 290 295 gac cag gga ggt cta gag gct gtc cgg cag gag atg agg cgc caa gag 963 Asp Gln Gly Gly Leu Glu Ala Val Arg Gln Glu Met Arg Arg Gln Glu 300 305 310 cca ctc cca cca cct ccg ccg cca tgc aga gga gga gga gga gga gga 1011 Pro Leu Pro Pro Pro Pro Pro Pro Cys Arg Gly Gly Gly Gly Gly Gly 315 320 325 gga gga gga gga gga gga gga gga gga gga gga ggc cag cct ctg aga 1059 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gln Pro Leu Arg 330 335 340 345 cct cct gtt ttg ggg agt aat aag ggt cgc tca cct cca ctg ccc cct 1107 Pro Pro Val Leu Gly Ser Asn Lys Gly Arg Ser Pro Pro Leu Pro Pro 350 355 360 gta cct atg ggg ggt gcc cca cct cca cca aca cca cga ggg ccc cca 1155 Val Pro Met Gly Gly Ala Pro Pro Pro Pro Thr Pro Arg Gly Pro Pro 365 370 375 cca cca ggc cga ggg ggt cct cct cca cca ccc cct cca gcc act gga 1203 Pro Pro Gly Arg Gly Gly Pro Pro Pro Pro Pro Pro Pro Ala Thr Gly 380 385 390 cga tct gga cca cca cct cct cca ctc cct gga gct ggg gga cca cca 1251 Arg Ser Gly Pro Pro Pro Pro Pro Leu Pro Gly Ala Gly Gly Pro Pro 395 400 405 gca ccg cca cca cca cca cca cca cca cca cct cca ccc tgc cct ggg 1299 Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Cys Pro Gly 410 415 420 425 agt gga ccc gcc cct ccc ccg ctc cct cct act cca gtg tct ggg ggg 1347 Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro Thr Pro Val Ser Gly Gly 430 435 440 agc cca gca cct ggt ggg ggc cgg ggt gca ctt ttg gac caa atc cgg 1395 Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg 445 450 455 cag gga att cag ctg aac aag acc cct gga gct cta gag aac tca gta 1443 Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val 460 465 470 cag caa cca ccc gcg cag cag tca gaa ggc cta gta ggt gcc ctg atg 1491 Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met 475 480 485 cat gtc atg cag aag agg agt aga gtc atc cat tcc tca gat gaa ggg 1539 His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly 490 495 500 505 gag gat cag acc ggc gag gat gaa gag gat gat gaa tgg gat gac 1584 Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp Asp Glu Trp Asp Asp 510 515 520 taaagtcatc ttccttccag caagccagtt cctctccaca ctcactctgc catctagatt 1644 ctgctcccgc tggcagcttc ccaattcacc tgttggggaa cctcataccc aatctaaagt 1704 acacatgacg tcacctttca cctctcataa ctcagggatg aaacaggata aaattgagtc 1764 tatgtgtctg agtgtgtgtt cattcacatc ctaaatgagt agtttgggtt tctttccctc 1824 acagtccctt ttggctttga tcttgctttg tgtgttttta ttgagccttt cacaagtatg 1884 atctattatt cctttaagat ttcagccata gccgggtgtg gtggcgcacg cctttaattc 1944 cagcagaagg gaggcagagg caggtggatt tctgagttcg agaccagcct ggtctacaga 2004 gtgagttcca ggacagccag ggctatacag agaaaccctg tctcaaaaaa ccaaaaaaaa 2064 aaaaa 2069 36 520 PRT Mus musculus 36 Met Asn Ser Gly Pro Gly Pro Val Gly Gly Arg Pro Gly Gly Arg Gly 1 5 10 15 Gly Pro Ala Val Gln Gln Asn Ile Pro Ser Asn Leu Leu Gln Asp His 20 25 30 Glu Asn Gln Arg Leu Phe Glu Leu Leu Gly Arg Lys Cys Trp Thr Leu 35 40 45 Ala Thr Thr Val Val Gln Leu Tyr Leu Ala Leu Pro Pro Gly Ala Glu 50 55 60 His Trp Thr Met Glu His Cys Gly Ala Val Cys Phe Val Lys Asp Asn 65 70 75 80 Pro Gln Lys Ser Tyr Phe Ile Arg Leu Tyr Ala Leu Gln Ala Gly Arg 85 90 95 Leu Leu Trp Glu Gln Glu Leu Tyr Ser Gln Leu Val Tyr Leu Thr Pro 100 105 110 Thr Pro Phe Phe His Thr Phe Ala Gly Asp Asp Cys Gln Val Gly Leu 115 120 125 Asn Phe Ala Asp Glu Ser Glu Ala Gln Ala Phe Arg Ala Leu Val Gln 130 135 140 Glu Lys Ile Gln Lys Arg Asn Gln Arg Gln Ser Gly Glu Arg Arg Gln 145 150 155 160 Leu Pro Pro Pro Pro Ala Pro Ile Asn Glu Glu Arg Arg Gly Gly Leu 165 170 175 Pro Pro Val Pro Pro His Pro Gly Gly Asp His Gly Gly Pro Ser Gly 180 185 190 Gly Pro Leu Ser Leu Gly Leu Val Thr Val Asp Ile Gln Asn Pro Asp 195 200 205 Ile Thr Ser Ser Arg Tyr Arg Gly Leu Pro Ala Pro Gly Pro Gly Pro 210 215 220 Thr Asp Lys Lys Arg Ser Gly Lys Lys Lys Ile Ser Lys Ala Asp Ile 225 230 235 240 Gly Ala Pro Ser Gly Phe Lys His Val Ser His Val Gly Trp Asp Pro 245 250 255 Gln Asn Gly Phe Asp Val Asn Asn Leu Asp Pro Asp Leu Arg Ser Leu 260 265 270 Phe Ser Arg Ala Gly Ile Ser Glu Ala Gln Leu Thr Asp Ala Glu Thr 275 280 285 Ser Lys Leu Ile Tyr Asp Phe Ile Glu Asp Gln Gly Gly Leu Glu Ala 290 295 300 Val Arg Gln Glu Met Arg Arg Gln Glu Pro Leu Pro Pro Pro Pro Pro 305 310 315 320 Pro Cys Arg Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 325 330 335 Gly Gly Gly Gly Gly Gln Pro Leu Arg Pro Pro Val Leu Gly Ser Asn 340 345 350 Lys Gly Arg Ser Pro Pro Leu Pro Pro Val Pro Met Gly Gly Ala Pro 355 360 365 Pro Pro Pro Thr Pro Arg Gly Pro Pro Pro Pro Gly Arg Gly Gly Pro 370 375 380 Pro Pro Pro Pro Pro Pro Ala Thr Gly Arg Ser Gly Pro Pro Pro Pro 385 390 395 400 Pro Leu Pro Gly Ala Gly Gly Pro Pro Ala Pro Pro Pro Pro Pro Pro 405 410 415 Pro Pro Pro Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro 420 425 430 Leu Pro Pro Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly 435 440 445 Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys 450 455 460 Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln 465 470 475 480 Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser 485 490 495 Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp 500 505 510 Glu Glu Asp Asp Glu Trp Asp Asp 515 520 37 303 DNA Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 37 cct cca ccc tgc cct ggg agt gga ccc gcc cct ccc ccg ctc cct cct 48 Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro 1 5 10 15 act cca gtg tct ggg ggg agc cca gca cct ggt ggg ggc cgg ggt gca 96 Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala 20 25 30 ctt ttg gac caa atc cgg cag gga att cag ctg aac aag acc cct gga 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly 35 40 45 gct cta gag aac tca gta cag caa cca ccc gcg cag cag tca gaa ggc 192 Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly 50 55 60 cta gta ggt gcc ctg atg cat gtc atg cag aag agg agt aga gtc atc 240 Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile 65 70 75 80 cat tcc tca gat gaa ggg gag gat cag acc ggc gag gat gaa gag gat 288 His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp 85 90 95 gat gaa tgg gat gac 303 Asp Glu Trp Asp Asp 100 38 101 PRT Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 38 Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro 1 5 10 15 Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly 35 40 45 Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly 50 55 60 Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile 65 70 75 80 His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp 85 90 95 Asp Glu Trp Asp Asp 100 39 258 DNA Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 39 cct cca ccc tgc cct ggg agt gga ccc gcc cct ccc ccg ctc cct cct 48 Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro 1 5 10 15 act cca gtg tct ggg ggg agc cca gca cct ggt ggg ggc cgg ggt gca 96 Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala 20 25 30 ctt ttg gac caa atc cgg cag gga att cag ctg aac aag acc cct gga 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly 35 40 45 gct cta gag aac tca gta cag caa cca ccc gcg cag cag tca gaa ggc 192 Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly 50 55 60 cta gta ggt gcc ctg atg cat gtc atg cag aag agg agt aga gtc atc 240 Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile 65 70 75 80 cat tcc tca gat gaa ggg 258 His Ser Ser Asp Glu Gly 85 40 86 PRT Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 40 Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro 1 5 10 15 Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly 35 40 45 Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly 50 55 60 Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile 65 70 75 80 His Ser Ser Asp Glu Gly 85 41 219 DNA Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 41 ggc cgg ggt gca ctt ttg gac caa atc cgg cag gga att cag ctg aac 48 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 aag acc cct gga gct cta gag aac tca gta cag caa cca ccc gcg cag 96 Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln 20 25 30 cag tca gaa ggc cta gta ggt gcc ctg atg cat gtc atg cag aag agg 144 Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 agt aga gtc atc cat tcc tca gat gaa ggg gag gat cag acc ggc gag 192 Ser Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu 50 55 60 gat gaa gag gat gat gaa tgg gat gac 219 Asp Glu Glu Asp Asp Glu Trp Asp Asp 65 70 42 73 PRT Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 42 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln 20 25 30 Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 Ser Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu 50 55 60 Asp Glu Glu Asp Asp Glu Trp Asp Asp 65 70 43 174 DNA Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 43 ggc cgg ggt gca ctt ttg gac caa atc cgg cag gga att cag ctg aac 48 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 aag acc cct gga gct cta gag aac tca gta cag caa cca ccc gcg cag 96 Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln 20 25 30 cag tca gaa ggc cta gta ggt gcc ctg atg cat gtc atg cag aag agg 144 Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 agt aga gtc atc cat tcc tca gat gaa ggg 174 Ser Arg Val Ile His Ser Ser Asp Glu Gly 50 55 44 58 PRT Artificial sequence Description of the artificial sequence Fragment of the murine WASP protein 44 Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn 1 5 10 15 Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln 20 25 30 Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg 35 40 45 Ser Arg Val Ile His Ser Ser Asp Glu Gly 50 55 45 1588 DNA Rattus rattus CDS (72)..(1574) 45 cggagtggga ccgagtgctc gcccaccacc agaagagacg gccctggaca ctccacccca 60 ccggcgacac c atg agc tcg ggc cag cag ccc ccg cgg agg gtc acc aac 110 Met Ser Ser Gly Gln Gln Pro Pro Arg Arg Val Thr Asn 1 5 10 gtg ggc tcc ctg ctg ctc acc ccg caa gaa aac gag tct ctt ttc tcc 158 Val Gly Ser Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Ser 15 20 25 ttc ctc ggc aag aaa tgt gtg act atg tct tca gca gtg gtg cag tta 206 Phe Leu Gly Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu 30 35 40 45 tat gca gct gat cgg aac tgt atg tgg tca aag aag tgc agt ggt gtt 254 Tyr Ala Ala Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val 50 55 60 gct tgt ctt gtt aag gac aat cct cag aga tct tat ttt tta aga ata 302 Ala Cys Leu Val Lys Asp Asn Pro Gln Arg Ser Tyr Phe Leu Arg Ile 65 70 75 ttt gac att aag gat ggg aaa tta ctg tgg gaa caa gag cta tac aat 350 Phe Asp Ile Lys Asp Gly Lys Leu Leu Trp Glu Gln Glu Leu Tyr Asn 80 85 90 aac ttt gta tat aat agt cct aga gga tat ttt cat acc ttt gct gga 398 Asn Phe Val Tyr Asn Ser Pro Arg Gly Tyr Phe His Thr Phe Ala Gly 95 100 105 gat act tgt caa gta gct ctt aat ttt gcc aat gaa gaa gaa gca aaa 446 Asp Thr Cys Gln Val Ala Leu Asn Phe Ala Asn Glu Glu Glu Ala Lys 110 115 120 125 aag ttc cga aaa gca gtt aca gac ctg ttg ggt cga cga caa agg aaa 494 Lys Phe Arg Lys Ala Val Thr Asp Leu Leu Gly Arg Arg Gln Arg Lys 130 135 140 tct gaa aaa aga cga gat gct cca aat ggt ccc aat cta ccc atg gct 542 Ser Glu Lys Arg Arg Asp Ala Pro Asn Gly Pro Asn Leu Pro Met Ala 145 150 155 aca gtt gac ata aaa aat cca gaa atc aca aca aac agg ttt tat agt 590 Thr Val Asp Ile Lys Asn Pro Glu Ile Thr Thr Asn Arg Phe Tyr Ser 160 165 170 tca caa gtc aac aac atc tcc cac acc aaa gaa aag aag aaa gga aaa 638 Ser Gln Val Asn Asn Ile Ser His Thr Lys Glu Lys Lys Lys Gly Lys 175 180 185 gct aaa aag aag aga tta acc aag gca gat att gga aca cca agt aat 686 Ala Lys Lys Lys Arg Leu Thr Lys Ala Asp Ile Gly Thr Pro Ser Asn 190 195 200 205 ttc cag cac att gga cat gtt ggt tgg gat cca aat aca ggt ttt gat 734 Phe Gln His Ile Gly His Val Gly Trp Asp Pro Asn Thr Gly Phe Asp 210 215 220 cta aat aat ttg gat cca gaa ttg aag aat ctt ttt gat atg tgt ggg 782 Leu Asn Asn Leu Asp Pro Glu Leu Lys Asn Leu Phe Asp Met Cys Gly 225 230 235 atc tct gag gcc cag ctt aaa gac aga gaa aca tca aaa gtt att tat 830 Ile Ser Glu Ala Gln Leu Lys Asp Arg Glu Thr Ser Lys Val Ile Tyr 240 245 250 gac ttt att gaa aaa aca gga ggt gta gaa gct gtt aaa aat gaa ctc 878 Asp Phe Ile Glu Lys Thr Gly Gly Val Glu Ala Val Lys Asn Glu Leu 255 260 265 cga agg caa gca cca cca cct cct cca ccc tca aga gga gga cct ccc 926 Arg Arg Gln Ala Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Pro Pro 270 275 280 285 cct cct cct ccc cct cct cac agc tca ggc cct cct ccc cct cct gcc 974 Pro Pro Pro Pro Pro Pro His Ser Ser Gly Pro Pro Pro Pro Pro Ala 290 295 300 cgt gga agg ggg gct cct ccc ccg cca cca tca aga gct cct act gct 1022 Arg Gly Arg Gly Ala Pro Pro Pro Pro Pro Ser Arg Ala Pro Thr Ala 305 310 315 gca cct cca cct cca cct cct tct agg cct ggt gtt gtc gtt cct cca 1070 Ala Pro Pro Pro Pro Pro Pro Ser Arg Pro Gly Val Val Val Pro Pro 320 325 330 cct cct cca aac agg atg tac cct cct cca cca cca gcc ctg cct tcc 1118 Pro Pro Pro Asn Arg Met Tyr Pro Pro Pro Pro Pro Ala Leu Pro Ser 335 340 345 tca gca cct tca ggc cca cca cca cct ccg cct ctg tct atg gca ggg 1166 Ser Ala Pro Ser Gly Pro Pro Pro Pro Pro Pro Leu Ser Met Ala Gly 350 355 360 365 tcc aca gca cca cca cct cct cca cca cct ccc cct cca cca ggg cca 1214 Ser Thr Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly Pro 370 375 380 cca cct ccc cct ggc ctg cct tct gat ggt gac cat caa gtt cca gct 1262 Pro Pro Pro Pro Gly Leu Pro Ser Asp Gly Asp His Gln Val Pro Ala 385 390 395 tct tca gga aac aaa gca gct ctt ttg gat caa att aga gag ggt gct 1310 Ser Ser Gly Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala 400 405 410 cag cta aaa aaa gtg gag cag aat agt cgg ccc gtg tcc tgc tca gga 1358 Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly 415 420 425 agg gat gca ctt cta gac cag ata cga cag ggc att cag ttg aaa tcc 1406 Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser 430 435 440 445 gtg tct gat ggc caa gag tcc aca cca cca acc ccc gcg ccc act tca 1454 Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser 450 455 460 gga att gtg ggt gcg ctg atg gaa gtg atg cag aaa agg agc aaa gcc 1502 Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala 465 470 475 att cat tcc tca gat gaa gat gaa gat gat gat gat gaa gaa gat ttt 1550 Ile His Ser Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe 480 485 490 cag gat gat gat gag tgg gaa gac tgatctatat tatt 1588 Gln Asp Asp Asp Glu Trp Glu Asp 495 500 46 501 PRT Rattus rattus 46 Met Ser Ser Gly Gln Gln Pro Pro Arg Arg Val Thr Asn Val Gly Ser 1 5 10 15 Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Ser Phe Leu Gly 20 25 30 Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu Tyr Ala Ala 35 40 45 Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val Ala Cys Leu 50 55 60 Val Lys Asp Asn Pro Gln Arg Ser Tyr Phe Leu Arg Ile Phe Asp Ile 65 70 75 80 Lys Asp Gly Lys Leu Leu Trp Glu Gln Glu Leu Tyr Asn Asn Phe Val 85 90 95 Tyr Asn Ser Pro Arg Gly Tyr Phe His Thr Phe Ala Gly Asp Thr Cys 100 105 110 Gln Val Ala Leu Asn Phe Ala Asn Glu Glu Glu Ala Lys Lys Phe Arg 115 120 125 Lys Ala Val Thr Asp Leu Leu Gly Arg Arg Gln Arg Lys Ser Glu Lys 130 135 140 Arg Arg Asp Ala Pro Asn Gly Pro Asn Leu Pro Met Ala Thr Val Asp 145 150 155 160 Ile Lys Asn Pro Glu Ile Thr Thr Asn Arg Phe Tyr Ser Ser Gln Val 165 170 175 Asn Asn Ile Ser His Thr Lys Glu Lys Lys Lys Gly Lys Ala Lys Lys 180 185 190 Lys Arg Leu Thr Lys Ala Asp Ile Gly Thr Pro Ser Asn Phe Gln His 195 200 205 Ile Gly His Val Gly Trp Asp Pro Asn Thr Gly Phe Asp Leu Asn Asn 210 215 220 Leu Asp Pro Glu Leu Lys Asn Leu Phe Asp Met Cys Gly Ile Ser Glu 225 230 235 240 Ala Gln Leu Lys Asp Arg Glu Thr Ser Lys Val Ile Tyr Asp Phe Ile 245 250 255 Glu Lys Thr Gly Gly Val Glu Ala Val Lys Asn Glu Leu Arg Arg Gln 260 265 270 Ala Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Pro Pro Pro Pro Pro 275 280 285 Pro Pro Pro His Ser Ser Gly Pro Pro Pro Pro Pro Ala Arg Gly Arg 290 295 300 Gly Ala Pro Pro Pro Pro Pro Ser Arg Ala Pro Thr Ala Ala Pro Pro 305 310 315 320 Pro Pro Pro Pro Ser Arg Pro Gly Val Val Val Pro Pro Pro Pro Pro 325 330 335 Asn Arg Met Tyr Pro Pro Pro Pro Pro Ala Leu Pro Ser Ser Ala Pro 340 345 350 Ser Gly Pro Pro Pro Pro Pro Pro Leu Ser Met Ala Gly Ser Thr Ala 355 360 365 Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly Pro Pro Pro Pro 370 375 380 Pro Gly Leu Pro Ser Asp Gly Asp His Gln Val Pro Ala Ser Ser Gly 385 390 395 400 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 405 410 415 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 420 425 430 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp 435 440 445 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 450 455 460 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 465 470 475 480 Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp 485 490 495 Asp Glu Trp Glu Asp 500 47 303 DNA Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 47 aac aaa gca gct ctt ttg gat caa att aga gag ggt gct cag cta aaa 48 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 aaa gtg gag cag aat agt cgg ccc gtg tcc tgc tca gga agg gat gca 96 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 ctt cta gac cag ata cga cag ggc att cag ttg aaa tcc gtg tct gat 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp 35 40 45 ggc caa gag tcc aca cca cca acc ccc gcg ccc act tca gga att gtg 192 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 ggt gcg ctg atg gaa gtg atg cag aaa agg agc aaa gcc att cat tcc 240 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 tca gat gaa gat gaa gat gat gat gat gaa gaa gat ttt cag gat gat 288 Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp 85 90 95 gat gag tgg gaa gac 303 Asp Glu Trp Glu Asp 100 48 101 PRT Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 48 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp 35 40 45 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp 85 90 95 Asp Glu Trp Glu Asp 100 49 252 DNA Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 49 aac aaa gca gct ctt ttg gat caa att aga gag ggt gct cag cta aaa 48 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 aaa gtg gag cag aat agt cgg ccc gtg tcc tgc tca gga agg gat gca 96 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 ctt cta gac cag ata cga cag ggc att cag ttg aaa tcc gtg tct gat 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp 35 40 45 ggc caa gag tcc aca cca cca acc ccc gcg ccc act tca gga att gtg 192 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 ggt gcg ctg atg gaa gtg atg cag aaa agg agc aaa gcc att cat tcc 240 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 tca gat gaa gat 252 Ser Asp Glu Asp 50 84 PRT Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 50 Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp 35 40 45 Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 Ser Asp Glu Asp 51 219 DNA Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 51 gga agg gat gca ctt cta gac cag ata cga cag ggc att cag ttg aaa 48 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 tcc gtg tct gat ggc caa gag tcc aca cca cca acc ccc gcg ccc act 96 Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 tca gga att gtg ggt gcg ctg atg gaa gtg atg cag aaa agg agc aaa 144 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 gcc att cat tcc tca gat gaa gat gaa gat gat gat gat gaa gaa gat 192 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp 50 55 60 ttt cag gat gat gat gag tgg gaa gac 219 Phe Gln Asp Asp Asp Glu Trp Glu Asp 65 70 52 73 PRT Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 52 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp 50 55 60 Phe Gln Asp Asp Asp Glu Trp Glu Asp 65 70 53 168 DNA Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 53 gga agg gat gca ctt cta gac cag ata cga cag ggc att cag ttg aaa 48 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 tcc gtg tct gat ggc caa gag tcc aca cca cca acc ccc gcg ccc act 96 Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 tca gga att gtg ggt gcg ctg atg gaa gtg atg cag aaa agg agc aaa 144 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 gcc att cat tcc tca gat gaa gat 168 Ala Ile His Ser Ser Asp Glu Asp 50 55 54 56 PRT Artificial sequence Description of the artificial sequence Fragment of the rat N-WASP protein 54 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 20 25 30 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 Ala Ile His Ser Ser Asp Glu Asp 50 55 55 1836 DNA Bos taurus CDS (288)..(1802) 55 gccgccgaag aaggttgggg gaggagttgg gagtttagcg cagtcgccgg agtgcgagga 60 caacgaccat ccggccagag cctaccccgg cgggaacggg gagcttccct ttctcacagc 120 ggcccgccgt cggctcctcc ttccgtggtc tcctccctgc gccggaggag ctgcgagatg 180 ctacgcctct gattcccctc ctcccgcccc tgtcacccag aaggggaacg agcgctcgcc 240 cactcgccgg agagacggcc ctggctccct accccgccgg cgaaacc atg agc tcc 296 Met Ser Ser 1 ggc cag cag cag ccg ccg ccg ccg cgg agg gtc acc aac gtg ggg tcc 344 Gly Gln Gln Gln Pro Pro Pro Pro Arg Arg Val Thr Asn Val Gly Ser 5 10 15 ctg ctg ctc acc ccg cag gag aac gag tcc ctc ttc acc ttc ctc ggc 392 Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Thr Phe Leu Gly 20 25 30 35 aag aaa tgt gtg acc atg tct tcg gca gtg gta cag tta tat gca gca 440 Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu Tyr Ala Ala 40 45 50 gat cgg aac tgt atg tgg tca aag aag tgc agt ggt gtt gct tgt ctt 488 Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val Ala Cys Leu 55 60 65 gtt aag gac aat cca cag aga tct tat ttt tta aga ata ttt gat atc 536 Val Lys Asp Asn Pro Gln Arg Ser Tyr Phe Leu Arg Ile Phe Asp Ile 70 75 80 aag gat ggg aaa cta ttg tgg gaa caa gag cta tac aat aac ttt gta 584 Lys Asp Gly Lys Leu Leu Trp Glu Gln Glu Leu Tyr Asn Asn Phe Val 85 90 95 tat aat agt cct aga gga tat ttt cat acc ttt gct gga gat acc tgt 632 Tyr Asn Ser Pro Arg Gly Tyr Phe His Thr Phe Ala Gly Asp Thr Cys 100 105 110 115 caa gtt gct ctt aat ttt gcc aat gaa gaa gaa gca aaa aaa ttc cga 680 Gln Val Ala Leu Asn Phe Ala Asn Glu Glu Glu Ala Lys Lys Phe Arg 120 125 130 aaa gca gtt aca gac ttg ttg gga cga cga caa agg aaa tct gag aaa 728 Lys Ala Val Thr Asp Leu Leu Gly Arg Arg Gln Arg Lys Ser Glu Lys 135 140 145 aga cga gac ccc cca aat ggt cct aat cta ccc atg gca aca gtt gac 776 Arg Arg Asp Pro Pro Asn Gly Pro Asn Leu Pro Met Ala Thr Val Asp 150 155 160 ata aaa aat cca gaa att aca aca aat aga ttt tat ggt ccg caa atc 824 Ile Lys Asn Pro Glu Ile Thr Thr Asn Arg Phe Tyr Gly Pro Gln Ile 165 170 175 aac aac atc tcc cat acc aaa gaa aag aaa aaa gga aaa gct aaa aag 872 Asn Asn Ile Ser His Thr Lys Glu Lys Lys Lys Gly Lys Ala Lys Lys 180 185 190 195 aag agg tta act aag gca gat att gga aca cca agc aat ttc caa cac 920 Lys Arg Leu Thr Lys Ala Asp Ile Gly Thr Pro Ser Asn Phe Gln His 200 205 210 att gga cat gtg ggt tgg gat ccg aat act ggc ttt gat ctg aat aat 968 Ile Gly His Val Gly Trp Asp Pro Asn Thr Gly Phe Asp Leu Asn Asn 215 220 225 ttg gat cca gaa ttg aag aat ctt ttt gat atg tgt gga atc tca gag 1016 Leu Asp Pro Glu Leu Lys Asn Leu Phe Asp Met Cys Gly Ile Ser Glu 230 235 240 gca caa ctt aaa gac aga gaa aca tca aaa gtt ata tat gac ttc att 1064 Ala Gln Leu Lys Asp Arg Glu Thr Ser Lys Val Ile Tyr Asp Phe Ile 245 250 255 gaa aaa aca gga ggt gtt gaa gct gtt aaa aat gaa ctg cga agg caa 1112 Glu Lys Thr Gly Gly Val Glu Ala Val Lys Asn Glu Leu Arg Arg Gln 260 265 270 275 gca cca cca cct cca cca cca tca agg gga ggg ccg ccc cct cct ccc 1160 Ala Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Pro Pro Pro Pro Pro 280 285 290 ccg cct cca cat agc tcg ggc cct cct ccc cct cct gcc agg gga aga 1208 Pro Pro Pro His Ser Ser Gly Pro Pro Pro Pro Pro Ala Arg Gly Arg 295 300 305 ggg gct cct cct cca cca cct tca aga gct ccc aca gct gca ccg cca 1256 Gly Ala Pro Pro Pro Pro Pro Ser Arg Ala Pro Thr Ala Ala Pro Pro 310 315 320 cca ccg cct cca tcc agg cca ggt gta gga gcc cct cca cca ccg cca 1304 Pro Pro Pro Pro Ser Arg Pro Gly Val Gly Ala Pro Pro Pro Pro Pro 325 330 335 aac agg atg tac cct cct cca ctt cca gct ctt ccc tcc tca gca cct 1352 Asn Arg Met Tyr Pro Pro Pro Leu Pro Ala Leu Pro Ser Ser Ala Pro 340 345 350 355 tca ggg cct cca cca cca cct cca cct ctg tca gtg agc ggg tca gtg 1400 Ser Gly Pro Pro Pro Pro Pro Pro Pro Leu Ser Val Ser Gly Ser Val 360 365 370 gca cca cca cct ccg ccg cca cct cca cct cca cca ggg cca cca cct 1448 Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly Pro Pro Pro 375 380 385 ccc cct ggc ctc cct tct gat ggt gac cac caa gtt cca act cct gca 1496 Pro Pro Gly Leu Pro Ser Asp Gly Asp His Gln Val Pro Thr Pro Ala 390 395 400 gga agc aaa gca gct ctt tta gat caa att aga gag ggt gct cag cta 1544 Gly Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu 405 410 415 aaa aaa gtg gaa cag aac agt cgg ccg gtg tcc tgc tct gga agg gat 1592 Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp 420 425 430 435 gca ctt tta gac cag ata cga cag ggt att caa ctg aaa tct gta act 1640 Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr 440 445 450 gat gcc cca gag tct aca cca cca gca cct gca ccc act tca gga att 1688 Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile 455 460 465 gta ggt gca tta atg gaa gtg atg cag aag agg agc aaa gcc att cat 1736 Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His 470 475 480 tct tca gac gaa gat gag gat gaa gat gat gat gaa gat ttt gag gat 1784 Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp 485 490 495 gat gat gaa tgg gaa gac tgatctatat attatatata tatattttta aggt 1836 Asp Asp Glu Trp Glu Asp 500 505 56 505 PRT Bos taurus 56 Met Ser Ser Gly Gln Gln Gln Pro Pro Pro Pro Arg Arg Val Thr Asn 1 5 10 15 Val Gly Ser Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Thr 20 25 30 Phe Leu Gly Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu 35 40 45 Tyr Ala Ala Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val 50 55 60 Ala Cys Leu Val Lys Asp Asn Pro Gln Arg Ser Tyr Phe Leu Arg Ile 65 70 75 80 Phe Asp Ile Lys Asp Gly Lys Leu Leu Trp Glu Gln Glu Leu Tyr Asn 85 90 95 Asn Phe Val Tyr Asn Ser Pro Arg Gly Tyr Phe His Thr Phe Ala Gly 100 105 110 Asp Thr Cys Gln Val Ala Leu Asn Phe Ala Asn Glu Glu Glu Ala Lys 115 120 125 Lys Phe Arg Lys Ala Val Thr Asp Leu Leu Gly Arg Arg Gln Arg Lys 130 135 140 Ser Glu Lys Arg Arg Asp Pro Pro Asn Gly Pro Asn Leu Pro Met Ala 145 150 155 160 Thr Val Asp Ile Lys Asn Pro Glu Ile Thr Thr Asn Arg Phe Tyr Gly 165 170 175 Pro Gln Ile Asn Asn Ile Ser His Thr Lys Glu Lys Lys Lys Gly Lys 180 185 190 Ala Lys Lys Lys Arg Leu Thr Lys Ala Asp Ile Gly Thr Pro Ser Asn 195 200 205 Phe Gln His Ile Gly His Val Gly Trp Asp Pro Asn Thr Gly Phe Asp 210 215 220 Leu Asn Asn Leu Asp Pro Glu Leu Lys Asn Leu Phe Asp Met Cys Gly 225 230 235 240 Ile Ser Glu Ala Gln Leu Lys Asp Arg Glu Thr Ser Lys Val Ile Tyr 245 250 255 Asp Phe Ile Glu Lys Thr Gly Gly Val Glu Ala Val Lys Asn Glu Leu 260 265 270 Arg Arg Gln Ala Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Pro Pro 275 280 285 Pro Pro Pro Pro Pro Pro His Ser Ser Gly Pro Pro Pro Pro Pro Ala 290 295 300 Arg Gly Arg Gly Ala Pro Pro Pro Pro Pro Ser Arg Ala Pro Thr Ala 305 310 315 320 Ala Pro Pro Pro Pro Pro Pro Ser Arg Pro Gly Val Gly Ala Pro Pro 325 330 335 Pro Pro Pro Asn Arg Met Tyr Pro Pro Pro Leu Pro Ala Leu Pro Ser 340 345 350 Ser Ala Pro Ser Gly Pro Pro Pro Pro Pro Pro Pro Leu Ser Val Ser 355 360 365 Gly Ser Val Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly 370 375 380 Pro Pro Pro Pro Pro Gly Leu Pro Ser Asp Gly Asp His Gln Val Pro 385 390 395 400 Thr Pro Ala Gly Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly 405 410 415 Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser 420 425 430 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 435 440 445 Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr 450 455 460 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 465 470 475 480 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp 485 490 495 Phe Glu Asp Asp Asp Glu Trp Glu Asp 500 505 57 303 DNA Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 57 agc aaa gca gct ctt tta gat caa att aga gag ggt gct cag cta aaa 48 Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 aaa gtg gaa cag aac agt cgg ccg gtg tcc tgc tct gga agg gat gca 96 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 ctt tta gac cag ata cga cag ggt att caa ctg aaa tct gta act gat 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp 35 40 45 gcc cca gag tct aca cca cca gca cct gca ccc act tca gga att gta 192 Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 ggt gca tta atg gaa gtg atg cag aag agg agc aaa gcc att cat tct 240 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 tca gac gaa gat gag gat gaa gat gat gat gaa gat ttt gag gat gat 288 Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp Asp 85 90 95 gat gaa tgg gaa gac 303 Asp Glu Trp Glu Asp 100 58 101 PRT Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 58 Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp 35 40 45 Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp Asp 85 90 95 Asp Glu Trp Glu Asp 100 59 252 DNA Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 59 agc aaa gca gct ctt tta gat caa att aga gag ggt gct cag cta aaa 48 Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 aaa gtg gaa cag aac agt cgg ccg gtg tcc tgc tct gga agg gat gca 96 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 ctt tta gac cag ata cga cag ggt att caa ctg aaa tct gta act gat 144 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp 35 40 45 gcc cca gag tct aca cca cca gca cct gca ccc act tca gga att gta 192 Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 ggt gca tta atg gaa gtg atg cag aag agg agc aaa gcc att cat tct 240 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 tca gac gaa gat 252 Ser Asp Glu Asp 60 84 PRT Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 60 Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys 1 5 10 15 Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala 20 25 30 Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp 35 40 45 Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val 50 55 60 Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser 65 70 75 80 Ser Asp Glu Asp 61 219 DNA Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 61 gga agg gat gca ctt tta gac cag ata cga cag ggt att caa ctg aaa 48 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 tct gta act gat gcc cca gag tct aca cca cca gca cct gca ccc act 96 Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr 20 25 30 tca gga att gta ggt gca tta atg gaa gtg atg cag aag agg agc aaa 144 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 gcc att cat tct tca gac gaa gat gag gat gaa gat gat gat gaa gat 192 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp 50 55 60 ttt gag gat gat gat gaa tgg gaa gac 219 Phe Glu Asp Asp Asp Glu Trp Glu Asp 65 70 62 73 PRT Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 62 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr 20 25 30 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp 50 55 60 Phe Glu Asp Asp Asp Glu Trp Glu Asp 65 70 63 168 DNA Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 63 gga agg gat gca ctt tta gac cag ata cga cag ggt att caa ctg aaa 48 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 tct gta act gat gcc cca gag tct aca cca cca gca cct gca ccc act 96 Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr 20 25 30 tca gga att gta ggt gca tta atg gaa gtg atg cag aag agg agc aaa 144 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 gcc att cat tct tca gac gaa gat 168 Ala Ile His Ser Ser Asp Glu Asp 50 55 64 56 PRT Artificial sequence Description of the artificial sequence Fragment of the bovine N-WASP protein 64 Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 1 5 10 15 Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr 20 25 30 Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys 35 40 45 Ala Ile His Ser Ser Asp Glu Asp 50 55 65 3023 DNA Saccharomyces cerevisiae CDS (772)..(2670) 65 agttagaaga taactcacta gacttaacac cagaaaatcc tactctgtaa taaaataatc 60 ccggggtaat ggattggatt tttctatcag gatcgtttac gtatatataa tacactgtcg 120 gagtttagcg cgcttacagc cgctacttgt ggagtccttt tttttttttt ttttttgggg 180 tttcagacat ccagtaaaga atagaaacaa gcaacaaact tcagaactga aacaatgctt 240 ttttaagtta tcgcctaaat atattcaaaa aatatagata tgctagattt tcaattatac 300 caaagttcat attttcaaaa tgaatgttaa caaaaagaca agttgatggc cctttttcat 360 aaagtatgcg tttagtttca agtaacgccg gctgacgtgg acgatttatc aaagaagtgg 420 ttttggaata ctcttctttt gcaattagaa aaaaggcaaa actaaatgca atgcaagcag 480 ttgcccatgg tacttgaaat tgtgtctctg gtttaaaaga tctatgatat aagtcttaac 540 tgatcttata gttgtttttt tttgaatttt ccaaatagtt tatatgatca ttgaatacgt 600 gcgagacgtc cgaaaagggg ccagtcaata cctatgaaaa aaaatcatga atatgtaata 660 ataaatattg aatgtagaat atacatagta gaaaaggaag tgctgtagcg attgccatct 720 ccgctacaaa ttacagttcg ttactttaag tgttgatagg cgtgatttaa t atg gga 777 Met Gly 1 ctc cta aac tct tca gat aag gaa att atc aaa agg gct cta cca aaa 825 Leu Leu Asn Ser Ser Asp Lys Glu Ile Ile Lys Arg Ala Leu Pro Lys 5 10 15 gcg tcg aat aag att att gat gtt acg gtg gct cga cta tac att gca 873 Ala Ser Asn Lys Ile Ile Asp Val Thr Val Ala Arg Leu Tyr Ile Ala 20 25 30 tac cct gat aaa aat gaa tgg cag tac act gga ctt tca gga gct ctt 921 Tyr Pro Asp Lys Asn Glu Trp Gln Tyr Thr Gly Leu Ser Gly Ala Leu 35 40 45 50 gct cta gta gac gat ctt gtg ggg aat act ttt ttt ttg aaa tta gtt 969 Ala Leu Val Asp Asp Leu Val Gly Asn Thr Phe Phe Leu Lys Leu Val 55 60 65 gac atc aat ggc cat aga gga gtt atc tgg gac caa gaa ttg tat gtg 1017 Asp Ile Asn Gly His Arg Gly Val Ile Trp Asp Gln Glu Leu Tyr Val 70 75 80 aat ttt gaa tac tat caa gac cgt act ttt ttt cat aca ttt gag atg 1065 Asn Phe Glu Tyr Tyr Gln Asp Arg Thr Phe Phe His Thr Phe Glu Met 85 90 95 gaa gaa tgc ttt gca ggt tta ttg ttt gta gat att aat gaa gca tcg 1113 Glu Glu Cys Phe Ala Gly Leu Leu Phe Val Asp Ile Asn Glu Ala Ser 100 105 110 cac ttt tta aag aga gtt caa aag cgt gaa aga tat gct aac agg aaa 1161 His Phe Leu Lys Arg Val Gln Lys Arg Glu Arg Tyr Ala Asn Arg Lys 115 120 125 130 act ttg ttg aac aaa aat gct gta gca tta acc aag aaa gta aga gaa 1209 Thr Leu Leu Asn Lys Asn Ala Val Ala Leu Thr Lys Lys Val Arg Glu 135 140 145 gaa caa aaa tct caa gtg gtg cac ggc cca aga ggg gag tca ttg att 1257 Glu Gln Lys Ser Gln Val Val His Gly Pro Arg Gly Glu Ser Leu Ile 150 155 160 gac aat caa agg aaa aga tat aat tat gaa gat gtg gac aca att cca 1305 Asp Asn Gln Arg Lys Arg Tyr Asn Tyr Glu Asp Val Asp Thr Ile Pro 165 170 175 act aca aag cat aag gct cct ccc cct cct ccg cca acg gcc gaa aca 1353 Thr Thr Lys His Lys Ala Pro Pro Pro Pro Pro Pro Thr Ala Glu Thr 180 185 190 ttt gat tca gac caa aca agt tca ttt tcc gat atc aat tcg aca aca 1401 Phe Asp Ser Asp Gln Thr Ser Ser Phe Ser Asp Ile Asn Ser Thr Thr 195 200 205 210 gca tcc gca ccg act acc cca gcc cct gct ctt cct cct gca tct cct 1449 Ala Ser Ala Pro Thr Thr Pro Ala Pro Ala Leu Pro Pro Ala Ser Pro 215 220 225 gaa gta aga aaa gaa gaa acg cat cca aag cat agt tta ccg cct tta 1497 Glu Val Arg Lys Glu Glu Thr His Pro Lys His Ser Leu Pro Pro Leu 230 235 240 cca aat cag ttt gcg cca tta cca gac cct cca caa cat aac tct cca 1545 Pro Asn Gln Phe Ala Pro Leu Pro Asp Pro Pro Gln His Asn Ser Pro 245 250 255 cct caa aat aac gcg cct tcg caa ccc caa agc aat cca ttt cca ttc 1593 Pro Gln Asn Asn Ala Pro Ser Gln Pro Gln Ser Asn Pro Phe Pro Phe 260 265 270 cca att cct gaa att ccc tcg aca cag tct gca aca aac cca ttt cca 1641 Pro Ile Pro Glu Ile Pro Ser Thr Gln Ser Ala Thr Asn Pro Phe Pro 275 280 285 290 ttt ccg gta cct cag cag cag ttt aat caa gct cct tca atg ggc ata 1689 Phe Pro Val Pro Gln Gln Gln Phe Asn Gln Ala Pro Ser Met Gly Ile 295 300 305 cca cag cag aat agg ccc ctt cca cag ttg cct aac aga aat aat cgg 1737 Pro Gln Gln Asn Arg Pro Leu Pro Gln Leu Pro Asn Arg Asn Asn Arg 310 315 320 cct gtg cca cct cct ccg cca atg cgt acc act act gaa ggt tca ggt 1785 Pro Val Pro Pro Pro Pro Pro Met Arg Thr Thr Thr Glu Gly Ser Gly 325 330 335 gtt cgc cta cct gct cct cca cct ccg cca agg cgt ggg cca gca cca 1833 Val Arg Leu Pro Ala Pro Pro Pro Pro Pro Arg Arg Gly Pro Ala Pro 340 345 350 ccg cct cca cca cat agg cac gta acc agt aat acc ctg aat tct gcc 1881 Pro Pro Pro Pro His Arg His Val Thr Ser Asn Thr Leu Asn Ser Ala 355 360 365 370 ggt gga aat agc ctc ctt cca cag gcc act gga aga aga ggg cca gca 1929 Gly Gly Asn Ser Leu Leu Pro Gln Ala Thr Gly Arg Arg Gly Pro Ala 375 380 385 cca cca cct cct cca aga gca tct cgc ccc aca cca aac gtt acg atg 1977 Pro Pro Pro Pro Pro Arg Ala Ser Arg Pro Thr Pro Asn Val Thr Met 390 395 400 caa caa aat cca caa cag tac aat aat tct aac cgc ccc ttt gga tat 2025 Gln Gln Asn Pro Gln Gln Tyr Asn Asn Ser Asn Arg Pro Phe Gly Tyr 405 410 415 cag aca aat agc aac atg tca tct cca ccc cct cct cca gtg aca act 2073 Gln Thr Asn Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr 420 425 430 ttc aat acc ctg aca cca caa atg act gca gca act gga caa cct gca 2121 Phe Asn Thr Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala 435 440 445 450 gtt ccc ctt cct cag aat act caa gca cct tcg caa gcc aca aat gtg 2169 Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val 455 460 465 cca gtg gca cca cca cct cct ccg gca tct tta ggc cag tcg cag ata 2217 Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile 470 475 480 cct cag tca gca ccc tca gca cct att ccg cca acg tta cca tcg acg 2265 Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr 485 490 495 acg agt gct gca cca cct ccg cca cca gca ttc cta act caa caa cct 2313 Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro 500 505 510 caa tct gga gga gct cca gct cca ccc cca cct cct caa atg cca gct 2361 Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala 515 520 525 530 aca tca aca tcc gga ggc ggt tca ttc gct gaa act act gga gat gca 2409 Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala 535 540 545 ggt cgt gat gca ctt tta gct tca att aga ggg gca ggt ggc ata ggc 2457 Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly 550 555 560 gct ttg aga aaa gtt gac aaa tcg cag cta gat aag ccc tca gtt tta 2505 Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu 565 570 575 ctg cag gaa gca cgt gga gaa tct gct tca cca cca gca gcg gct gga 2553 Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly 580 585 590 aat gga ggc aca cct ggt gga cct ccg gct tct tta gca gat gcg ttg 2601 Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu 595 600 605 610 gca gca gct tta aac aaa aga aaa act aaa gtg gga gct cat gac gat 2649 Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp 615 620 625 atg gac aat ggt gat gat tgg taatggaatg caaacaaaga tgaaactact 2700 Met Asp Asn Gly Asp Asp Trp 630 gttatagaaa atatgtaatt ttatgtactc actattaatg atcaaagtaa ttgctctttt 2760 tatgtatagt ttctttaatc ggaggaaatt ttgatatagg ttcaaaggcg gtcagtgatt 2820 gaatgatcaa ggtaatagtc gggctacaat gatggccatc cctatggccg tttcaaatgt 2880 ttgagaaaat gatgtatagt aaatcctaga ttttagcagt tcgaatcaaa aacccatgta 2940 aaaagggtaa atatttccta attataatat ttttgtttaa ttacacatgt agaacaataa 3000 aagtatagaa ttttagatag tat 3023 66 633 PRT Saccharomyces cerevisiae 66 Met Gly Leu Leu Asn Ser Ser Asp Lys Glu Ile Ile Lys Arg Ala Leu 1 5 10 15 Pro Lys Ala Ser Asn Lys Ile Ile Asp Val Thr Val Ala Arg Leu Tyr 20 25 30 Ile Ala Tyr Pro Asp Lys Asn Glu Trp Gln Tyr Thr Gly Leu Ser Gly 35 40 45 Ala Leu Ala Leu Val Asp Asp Leu Val Gly Asn Thr Phe Phe Leu Lys 50 55 60 Leu Val Asp Ile Asn Gly His Arg Gly Val Ile Trp Asp Gln Glu Leu 65 70 75 80 Tyr Val Asn Phe Glu Tyr Tyr Gln Asp Arg Thr Phe Phe His Thr Phe 85 90 95 Glu Met Glu Glu Cys Phe Ala Gly Leu Leu Phe Val Asp Ile Asn Glu 100 105 110 Ala Ser His Phe Leu Lys Arg Val Gln Lys Arg Glu Arg Tyr Ala Asn 115 120 125 Arg Lys Thr Leu Leu Asn Lys Asn Ala Val Ala Leu Thr Lys Lys Val 130 135 140 Arg Glu Glu Gln Lys Ser Gln Val Val His Gly Pro Arg Gly Glu Ser 145 150 155 160 Leu Ile Asp Asn Gln Arg Lys Arg Tyr Asn Tyr Glu Asp Val Asp Thr 165 170 175 Ile Pro Thr Thr Lys His Lys Ala Pro Pro Pro Pro Pro Pro Thr Ala 180 185 190 Glu Thr Phe Asp Ser Asp Gln Thr Ser Ser Phe Ser Asp Ile Asn Ser 195 200 205 Thr Thr Ala Ser Ala Pro Thr Thr Pro Ala Pro Ala Leu Pro Pro Ala 210 215 220 Ser Pro Glu Val Arg Lys Glu Glu Thr His Pro Lys His Ser Leu Pro 225 230 235 240 Pro Leu Pro Asn Gln Phe Ala Pro Leu Pro Asp Pro Pro Gln His Asn 245 250 255 Ser Pro Pro Gln Asn Asn Ala Pro Ser Gln Pro Gln Ser Asn Pro Phe 260 265 270 Pro Phe Pro Ile Pro Glu Ile Pro Ser Thr Gln Ser Ala Thr Asn Pro 275 280 285 Phe Pro Phe Pro Val Pro Gln Gln Gln Phe Asn Gln Ala Pro Ser Met 290 295 300 Gly Ile Pro Gln Gln Asn Arg Pro Leu Pro Gln Leu Pro Asn Arg Asn 305 310 315 320 Asn Arg Pro Val Pro Pro Pro Pro Pro Met Arg Thr Thr Thr Glu Gly 325 330 335 Ser Gly Val Arg Leu Pro Ala Pro Pro Pro Pro Pro Arg Arg Gly Pro 340 345 350 Ala Pro Pro Pro Pro Pro His Arg His Val Thr Ser Asn Thr Leu Asn 355 360 365 Ser Ala Gly Gly Asn Ser Leu Leu Pro Gln Ala Thr Gly Arg Arg Gly 370 375 380 Pro Ala Pro Pro Pro Pro Pro Arg Ala Ser Arg Pro Thr Pro Asn Val 385 390 395 400 Thr Met Gln Gln Asn Pro Gln Gln Tyr Asn Asn Ser Asn Arg Pro Phe 405 410 415 Gly Tyr Gln Thr Asn Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val 420 425 430 Thr Thr Phe Asn Thr Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln 435 440 445 Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr 450 455 460 Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser 465 470 475 480 Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro 485 490 495 Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln 500 505 510 Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met 515 520 525 Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly 530 535 540 Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly 545 550 555 560 Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser 565 570 575 Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala 580 585 590 Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp 595 600 605 Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His 610 615 620 Asp Asp Met Asp Asn Gly Asp Asp Trp 625 630 67 636 DNA Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 67 agc aac atg tca tct cca ccc cct cct cca gtg aca act ttc aat acc 48 Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr 1 5 10 15 ctg aca cca caa atg act gca gca act gga caa cct gca gtt ccc ctt 96 Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu 20 25 30 cct cag aat act caa gca cct tcg caa gcc aca aat gtg cca gtg gca 144 Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala 35 40 45 cca cca cct cct ccg gca tct tta ggc cag tcg cag ata cct cag tca 192 Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser 50 55 60 gca ccc tca gca cct att ccg cca acg tta cca tcg acg acg agt gct 240 Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala 65 70 75 80 gca cca cct ccg cca cca gca ttc cta act caa caa cct caa tct gga 288 Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly 85 90 95 gga gct cca gct cca ccc cca cct cct caa atg cca gct aca tca aca 336 Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr 100 105 110 tcc gga ggc ggt tca ttc gct gaa act act gga gat gca ggt cgt gat 384 Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp 115 120 125 gca ctt tta gct tca att aga ggg gca ggt ggc ata ggc gct ttg aga 432 Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg 130 135 140 aaa gtt gac aaa tcg cag cta gat aag ccc tca gtt tta ctg cag gaa 480 Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu 145 150 155 160 gca cgt gga gaa tct gct tca cca cca gca gcg gct gga aat gga ggc 528 Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly 165 170 175 aca cct ggt gga cct ccg gct tct tta gca gat gcg ttg gca gca gct 576 Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala 180 185 190 tta aac aaa aga aaa act aaa gtg gga gct cat gac gat atg gac aat 624 Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp Met Asp Asn 195 200 205 ggt gat gat tgg 636 Gly Asp Asp Trp 210 68 212 PRT Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 68 Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr 1 5 10 15 Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu 20 25 30 Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala 35 40 45 Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser 50 55 60 Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala 65 70 75 80 Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly 85 90 95 Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr 100 105 110 Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp 115 120 125 Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg 130 135 140 Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu 145 150 155 160 Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly 165 170 175 Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala 180 185 190 Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp Met Asp Asn 195 200 205 Gly Asp Asp Trp 210 69 609 DNA Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 69 agc aac atg tca tct cca ccc cct cct cca gtg aca act ttc aat acc 48 Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr 1 5 10 15 ctg aca cca caa atg act gca gca act gga caa cct gca gtt ccc ctt 96 Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu 20 25 30 cct cag aat act caa gca cct tcg caa gcc aca aat gtg cca gtg gca 144 Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala 35 40 45 cca cca cct cct ccg gca tct tta ggc cag tcg cag ata cct cag tca 192 Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser 50 55 60 gca ccc tca gca cct att ccg cca acg tta cca tcg acg acg agt gct 240 Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala 65 70 75 80 gca cca cct ccg cca cca gca ttc cta act caa caa cct caa tct gga 288 Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly 85 90 95 gga gct cca gct cca ccc cca cct cct caa atg cca gct aca tca aca 336 Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr 100 105 110 tcc gga ggc ggt tca ttc gct gaa act act gga gat gca ggt cgt gat 384 Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp 115 120 125 gca ctt tta gct tca att aga ggg gca ggt ggc ata ggc gct ttg aga 432 Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg 130 135 140 aaa gtt gac aaa tcg cag cta gat aag ccc tca gtt tta ctg cag gaa 480 Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu 145 150 155 160 gca cgt gga gaa tct gct tca cca cca gca gcg gct gga aat gga ggc 528 Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly 165 170 175 aca cct ggt gga cct ccg gct tct tta gca gat gcg ttg gca gca gct 576 Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala 180 185 190 tta aac aaa aga aaa act aaa gtg gga gct cat 609 Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His 195 200 70 203 PRT Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 70 Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr 1 5 10 15 Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu 20 25 30 Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala 35 40 45 Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser 50 55 60 Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala 65 70 75 80 Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly 85 90 95 Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr 100 105 110 Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp 115 120 125 Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg 130 135 140 Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu 145 150 155 160 Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly 165 170 175 Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala 180 185 190 Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His 195 200 71 561 DNA Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 71 gga caa cct gca gtt ccc ctt cct cag aat act caa gca cct tcg caa 48 Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln 1 5 10 15 gcc aca aat gtg cca gtg gca cca cca cct cct ccg gca tct tta ggc 96 Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly 20 25 30 cag tcg cag ata cct cag tca gca ccc tca gca cct att ccg cca acg 144 Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr 35 40 45 tta cca tcg acg acg agt gct gca cca cct ccg cca cca gca ttc cta 192 Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu 50 55 60 act caa caa cct caa tct gga gga gct cca gct cca ccc cca cct cct 240 Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro 65 70 75 80 caa atg cca gct aca tca aca tcc gga ggc ggt tca ttc gct gaa act 288 Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr 85 90 95 act gga gat gca ggt cgt gat gca ctt tta gct tca att aga ggg gca 336 Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala 100 105 110 ggt ggc ata ggc gct ttg aga aaa gtt gac aaa tcg cag cta gat aag 384 Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys 115 120 125 ccc tca gtt tta ctg cag gaa gca cgt gga gaa tct gct tca cca cca 432 Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro 130 135 140 gca gcg gct gga aat gga ggc aca cct ggt gga cct ccg gct tct tta 480 Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu 145 150 155 160 gca gat gcg ttg gca gca gct tta aac aaa aga aaa act aaa gtg gga 528 Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly 165 170 175 gct cat gac gat atg gac aat ggt gat gat tgg 561 Ala His Asp Asp Met Asp Asn Gly Asp Asp Trp 180 185 72 187 PRT Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 72 Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln 1 5 10 15 Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly 20 25 30 Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr 35 40 45 Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu 50 55 60 Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro 65 70 75 80 Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr 85 90 95 Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala 100 105 110 Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys 115 120 125 Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro 130 135 140 Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu 145 150 155 160 Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly 165 170 175 Ala His Asp Asp Met Asp Asn Gly Asp Asp Trp 180 185 73 534 DNA Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 73 gga caa cct gca gtt ccc ctt cct cag aat act caa gca cct tcg caa 48 Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln 1 5 10 15 gcc aca aat gtg cca gtg gca cca cca cct cct ccg gca tct tta ggc 96 Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly 20 25 30 cag tcg cag ata cct cag tca gca ccc tca gca cct att ccg cca acg 144 Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr 35 40 45 tta cca tcg acg acg agt gct gca cca cct ccg cca cca gca ttc cta 192 Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu 50 55 60 act caa caa cct caa tct gga gga gct cca gct cca ccc cca cct cct 240 Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro 65 70 75 80 caa atg cca gct aca tca aca tcc gga ggc ggt tca ttc gct gaa act 288 Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr 85 90 95 act gga gat gca ggt cgt gat gca ctt tta gct tca att aga ggg gca 336 Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala 100 105 110 ggt ggc ata ggc gct ttg aga aaa gtt gac aaa tcg cag cta gat aag 384 Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys 115 120 125 ccc tca gtt tta ctg cag gaa gca cgt gga gaa tct gct tca cca cca 432 Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro 130 135 140 gca gcg gct gga aat gga ggc aca cct ggt gga cct ccg gct tct tta 480 Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu 145 150 155 160 gca gat gcg ttg gca gca gct tta aac aaa aga aaa act aaa gtg gga 528 Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly 165 170 175 gct cat 534 Ala His 74 178 PRT Artificial sequence Description of the artificial sequence Fragment of the Saccharomyces cerevisiae Las17 protein 74 Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln 1 5 10 15 Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly 20 25 30 Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr 35 40 45 Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu 50 55 60 Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro 65 70 75 80 Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr 85 90 95 Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala 100 105 110 Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys 115 120 125 Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro 130 135 140 Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu 145 150 155 160 Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly 165 170 175 Ala His 75 2454 DNA Schizosaccharomyces pombe CDS (404)..(2125) 75 ttctaataat taatgattat gattaagtca tttttttaat aatcttataa taaactaaca 60 ttatgagaca agcaaacttc gtatggttga ataaatttta tttacctctt tacaatgagg 120 acgataagta tgtagaatgt aaaaaatatt aaacccgaat taatgtctca agttttatta 180 atctataaac agttaatata attagcaaaa tttaccagct gctaataagt gcgttgcaaa 240 tttttatagt acatagcgta gtatagtata gtatactaca ctaattatca ctcattggct 300 tgttaactac agtgaaaatg ctaacaaacg ggaggaacca aaacaccact tataccactg 360 tgagacagca atttttgaat tgcattacaa tccgaaaatt caa atg cct cca tct 415 Met Pro Pro Ser 1 tcc tct ata act caa gag gat aag gca act atc cgt aaa tac ata cct 463 Ser Ser Ile Thr Gln Glu Asp Lys Ala Thr Ile Arg Lys Tyr Ile Pro 5 10 15 20 aaa agc aca aat aaa atc att gca gca gcc gtc gtc aag cta tat gta 511 Lys Ser Thr Asn Lys Ile Ile Ala Ala Ala Val Val Lys Leu Tyr Val 25 30 35 gct tat cct gat ccg aac aaa tgg aat tat aca ggt ctt tgt ggt gct 559 Ala Tyr Pro Asp Pro Asn Lys Trp Asn Tyr Thr Gly Leu Cys Gly Ala 40 45 50 ctt gta ttg tcc tat gat aca aca gca aaa tgc tgt tgg ttt aaa ctg 607 Leu Val Leu Ser Tyr Asp Thr Thr Ala Lys Cys Cys Trp Phe Lys Leu 55 60 65 gtt gac gtt gtg aat aat agt ggt ata ata tgg gac caa gag ctt tat 655 Val Asp Val Val Asn Asn Ser Gly Ile Ile Trp Asp Gln Glu Leu Tyr 70 75 80 caa aat atg gac tat cgc caa gat cgt aca ttt ttt cat tct ttc gag 703 Gln Asn Met Asp Tyr Arg Gln Asp Arg Thr Phe Phe His Ser Phe Glu 85 90 95 100 ctt gat aaa tgc cta gca ggt ttt agt ttt gca aac gag aca gac gct 751 Leu Asp Lys Cys Leu Ala Gly Phe Ser Phe Ala Asn Glu Thr Asp Ala 105 110 115 caa aaa ttt tac aaa aag gtt tta gat aaa ggt tgc cat cct gaa tca 799 Gln Lys Phe Tyr Lys Lys Val Leu Asp Lys Gly Cys His Pro Glu Ser 120 125 130 att gag aat ccg gtt ttg tca ttt att acc aga aaa ggt tct tct aga 847 Ile Glu Asn Pro Val Leu Ser Phe Ile Thr Arg Lys Gly Ser Ser Arg 135 140 145 cat gcg cct aac aac agc aat atc caa cct ccc tca gct gct cct cct 895 His Ala Pro Asn Asn Ser Asn Ile Gln Pro Pro Ser Ala Ala Pro Pro 150 155 160 gta cct gga aag gaa aat tat aat gct gtt gga tct aaa agt ccc aat 943 Val Pro Gly Lys Glu Asn Tyr Asn Ala Val Gly Ser Lys Ser Pro Asn 165 170 175 180 gag ccc gag ctt tta aat tcg ctt gat ccg agc tta att gat tct cta 991 Glu Pro Glu Leu Leu Asn Ser Leu Asp Pro Ser Leu Ile Asp Ser Leu 185 190 195 atg aag atg ggc att tcc cag gat caa att gct gaa aac gca gat ttc 1039 Met Lys Met Gly Ile Ser Gln Asp Gln Ile Ala Glu Asn Ala Asp Phe 200 205 210 gtc aaa gcg tac ctt aat gaa tca gct ggt aca cct acc agt act tct 1087 Val Lys Ala Tyr Leu Asn Glu Ser Ala Gly Thr Pro Thr Ser Thr Ser 215 220 225 gca cct ccc atc cct cca agc att cct tcc tct cgt ccc cca gag cgt 1135 Ala Pro Pro Ile Pro Pro Ser Ile Pro Ser Ser Arg Pro Pro Glu Arg 230 235 240 gtt cct tct gtg tct gca cct gct cct ccc cca att cca cct cca tct 1183 Val Pro Ser Val Ser Ala Pro Ala Pro Pro Pro Ile Pro Pro Pro Ser 245 250 255 260 aat gga act gtc tct tct cct cct aac tcc cct ccc cgt cct atc gct 1231 Asn Gly Thr Val Ser Ser Pro Pro Asn Ser Pro Pro Arg Pro Ile Ala 265 270 275 cct gtt tcg atg aat cct gct att aat tcc acc tcg aaa cct cca ctc 1279 Pro Val Ser Met Asn Pro Ala Ile Asn Ser Thr Ser Lys Pro Pro Leu 280 285 290 cct cca cca tct tca aga gtc agt gcg gca gct cta gct gct aac aaa 1327 Pro Pro Pro Ser Ser Arg Val Ser Ala Ala Ala Leu Ala Ala Asn Lys 295 300 305 aaa cga cct cct ccg cct ccg cct cca tcc cgt cgt aat cgt ggt aaa 1375 Lys Arg Pro Pro Pro Pro Pro Pro Pro Ser Arg Arg Asn Arg Gly Lys 310 315 320 cca ccg att ggt aat ggt tct tct aac tcg tct ctt cct cca cct cca 1423 Pro Pro Ile Gly Asn Gly Ser Ser Asn Ser Ser Leu Pro Pro Pro Pro 325 330 335 340 cca cct cct aga tct aat gct gct ggc tca att cct ttg ccg cct caa 1471 Pro Pro Pro Arg Ser Asn Ala Ala Gly Ser Ile Pro Leu Pro Pro Gln 345 350 355 ggt aga tct gct cct cct cca cct cct cca agg tct gct cct tcc act 1519 Gly Arg Ser Ala Pro Pro Pro Pro Pro Pro Arg Ser Ala Pro Ser Thr 360 365 370 ggg aga caa cca ccc cct tta tct tca tct cgt gca gtt tca aac cca 1567 Gly Arg Gln Pro Pro Pro Leu Ser Ser Ser Arg Ala Val Ser Asn Pro 375 380 385 cca gcc cct cct cca gct att cct ggt cgt tct gcg cct gca ctt ccc 1615 Pro Ala Pro Pro Pro Ala Ile Pro Gly Arg Ser Ala Pro Ala Leu Pro 390 395 400 cct ctt ggt aat gca tca cga aca agc aca cct cct gtc cct aca cct 1663 Pro Leu Gly Asn Ala Ser Arg Thr Ser Thr Pro Pro Val Pro Thr Pro 405 410 415 420 cct tct ctt cct cct agt gca cct cca tct ttg ccc ccc agt gca cca 1711 Pro Ser Leu Pro Pro Ser Ala Pro Pro Ser Leu Pro Pro Ser Ala Pro 425 430 435 cct tct cta cct atg ggc gca cca gct gct ccc ccc cta cca cct agt 1759 Pro Ser Leu Pro Met Gly Ala Pro Ala Ala Pro Pro Leu Pro Pro Ser 440 445 450 gca cca att gct cct cct cta ccc gct ggt atg cca gct gct cca cca 1807 Ala Pro Ile Ala Pro Pro Leu Pro Ala Gly Met Pro Ala Ala Pro Pro 455 460 465 ttg cct ccc gct gca cca gct cct cct cca gct cca gct cct gcg ccc 1855 Leu Pro Pro Ala Ala Pro Ala Pro Pro Pro Ala Pro Ala Pro Ala Pro 470 475 480 gcc gcg cct gtt gct tcg ata gct gaa ttg cct caa caa gac ggc cgt 1903 Ala Ala Pro Val Ala Ser Ile Ala Glu Leu Pro Gln Gln Asp Gly Arg 485 490 495 500 gct aat tta atg gcc agt atc aga gcc agc ggt ggt atg gat tta ctg 1951 Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu 505 510 515 aaa agc agg aaa gta tct gct tct cct agt gtc gca tct aca aaa act 1999 Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr 520 525 530 tcg aat cct ccg gta gaa gca ccc cct tct aac aat ctt atg gat gca 2047 Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala 535 540 545 ttg gca agc gct ttg aac caa cgt aaa acc aaa gtc gct cag agt gac 2095 Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp 550 555 560 gaa gag gat gaa gac gac gat gag tgg gac tagttattaa tatctttgaa 2145 Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp 565 570 attacctata cttttttgat tcacacagtc ttttaaagtt ttgttaaacg acttcactat 2205 ttttatttgg atttgtgttt attgtattag agcaaacacc atttattcta aattgaataa 2265 cgcgaatttg tgttgatatt actattcata tatcgcaaca cagtgtgtat ctttacttta 2325 ttgtaagtat gggagcagtc acacatttcg gtaccacaac tttagaaacg tcaagttcaa 2385 gtccttccac aaccaaaaac gtttggtcaa atagaaacaa atggatcctc tagagtcgac 2445 ctgcagcaa 2454 76 574 PRT Schizosaccharomyces pombe 76 Met Pro Pro Ser Ser Ser Ile Thr Gln Glu Asp Lys Ala Thr Ile Arg 1 5 10 15 Lys Tyr Ile Pro Lys Ser Thr Asn Lys Ile Ile Ala Ala Ala Val Val 20 25 30 Lys Leu Tyr Val Ala Tyr Pro Asp Pro Asn Lys Trp Asn Tyr Thr Gly 35 40 45 Leu Cys Gly Ala Leu Val Leu Ser Tyr Asp Thr Thr Ala Lys Cys Cys 50 55 60 Trp Phe Lys Leu Val Asp Val Val Asn Asn Ser Gly Ile Ile Trp Asp 65 70 75 80 Gln Glu Leu Tyr Gln Asn Met Asp Tyr Arg Gln Asp Arg Thr Phe Phe 85 90 95 His Ser Phe Glu Leu Asp Lys Cys Leu Ala Gly Phe Ser Phe Ala Asn 100 105 110 Glu Thr Asp Ala Gln Lys Phe Tyr Lys Lys Val Leu Asp Lys Gly Cys 115 120 125 His Pro Glu Ser Ile Glu Asn Pro Val Leu Ser Phe Ile Thr Arg Lys 130 135 140 Gly Ser Ser Arg His Ala Pro Asn Asn Ser Asn Ile Gln Pro Pro Ser 145 150 155 160 Ala Ala Pro Pro Val Pro Gly Lys Glu Asn Tyr Asn Ala Val Gly Ser 165 170 175 Lys Ser Pro Asn Glu Pro Glu Leu Leu Asn Ser Leu Asp Pro Ser Leu 180 185 190 Ile Asp Ser Leu Met Lys Met Gly Ile Ser Gln Asp Gln Ile Ala Glu 195 200 205 Asn Ala Asp Phe Val Lys Ala Tyr Leu Asn Glu Ser Ala Gly Thr Pro 210 215 220 Thr Ser Thr Ser Ala Pro Pro Ile Pro Pro Ser Ile Pro Ser Ser Arg 225 230 235 240 Pro Pro Glu Arg Val Pro Ser Val Ser Ala Pro Ala Pro Pro Pro Ile 245 250 255 Pro Pro Pro Ser Asn Gly Thr Val Ser Ser Pro Pro Asn Ser Pro Pro 260 265 270 Arg Pro Ile Ala Pro Val Ser Met Asn Pro Ala Ile Asn Ser Thr Ser 275 280 285 Lys Pro Pro Leu Pro Pro Pro Ser Ser Arg Val Ser Ala Ala Ala Leu 290 295 300 Ala Ala Asn Lys Lys Arg Pro Pro Pro Pro Pro Pro Pro Ser Arg Arg 305 310 315 320 Asn Arg Gly Lys Pro Pro Ile Gly Asn Gly Ser Ser Asn Ser Ser Leu 325 330 335 Pro Pro Pro Pro Pro Pro Pro Arg Ser Asn Ala Ala Gly Ser Ile Pro 340 345 350 Leu Pro Pro Gln Gly Arg Ser Ala Pro Pro Pro Pro Pro Pro Arg Ser 355 360 365 Ala Pro Ser Thr Gly Arg Gln Pro Pro Pro Leu Ser Ser Ser Arg Ala 370 375 380 Val Ser Asn Pro Pro Ala Pro Pro Pro Ala Ile Pro Gly Arg Ser Ala 385 390 395 400 Pro Ala Leu Pro Pro Leu Gly Asn Ala Ser Arg Thr Ser Thr Pro Pro 405 410 415 Val Pro Thr Pro Pro Ser Leu Pro Pro Ser Ala Pro Pro Ser Leu Pro 420 425 430 Pro Ser Ala Pro Pro Ser Leu Pro Met Gly Ala Pro Ala Ala Pro Pro 435 440 445 Leu Pro Pro Ser Ala Pro Ile Ala Pro Pro Leu Pro Ala Gly Met Pro 450 455 460 Ala Ala Pro Pro Leu Pro Pro Ala Ala Pro Ala Pro Pro Pro Ala Pro 465 470 475 480 Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala Glu Leu Pro Gln 485 490 495 Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly 500 505 510 Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala 515 520 525 Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn 530 535 540 Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val 545 550 555 560 Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp 565 570 77 294 DNA Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 77 cct cca gct cca gct cct gcg ccc gcc gcg cct gtt gct tcg ata gct 48 Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala 1 5 10 15 gaa ttg cct caa caa gac ggc cgt gct aat tta atg gcc agt atc aga 96 Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg 20 25 30 gcc agc ggt ggt atg gat tta ctg aaa agc agg aaa gta tct gct tct 144 Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser 35 40 45 cct agt gtc gca tct aca aaa act tcg aat cct ccg gta gaa gca ccc 192 Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro 50 55 60 cct tct aac aat ctt atg gat gca ttg gca agc gct ttg aac caa cgt 240 Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg 65 70 75 80 aaa acc aaa gtc gct cag agt gac gaa gag gat gaa gac gac gat gag 288 Lys Thr Lys Val Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu 85 90 95 tgg gac 294 Trp Asp 78 98 PRT Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 78 Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala 1 5 10 15 Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg 20 25 30 Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser 35 40 45 Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro 50 55 60 Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg 65 70 75 80 Lys Thr Lys Val Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu 85 90 95 Trp Asp 79 267 DNA Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 79 cct cca gct cca gct cct gcg ccc gcc gcg cct gtt gct tcg ata gct 48 Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala 1 5 10 15 gaa ttg cct caa caa gac ggc cgt gct aat tta atg gcc agt atc aga 96 Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg 20 25 30 gcc agc ggt ggt atg gat tta ctg aaa agc agg aaa gta tct gct tct 144 Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser 35 40 45 cct agt gtc gca tct aca aaa act tcg aat cct ccg gta gaa gca ccc 192 Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro 50 55 60 cct tct aac aat ctt atg gat gca ttg gca agc gct ttg aac caa cgt 240 Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg 65 70 75 80 aaa acc aaa gtc gct cag agt gac gaa 267 Lys Thr Lys Val Ala Gln Ser Asp Glu 85 80 89 PRT Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 80 Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala 1 5 10 15 Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg 20 25 30 Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser 35 40 45 Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro 50 55 60 Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg 65 70 75 80 Lys Thr Lys Val Ala Gln Ser Asp Glu 85 81 222 DNA Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 81 gct aat tta atg gcc agt atc aga gcc agc ggt ggt atg gat tta ctg 48 Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu 1 5 10 15 aaa agc agg aaa gta tct gct tct cct agt gtc gca tct aca aaa act 96 Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr 20 25 30 tcg aat cct ccg gta gaa gca ccc cct tct aac aat ctt atg gat gca 144 Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala 35 40 45 ttg gca agc gct ttg aac caa cgt aaa acc aaa gtc gct cag agt gac 192 Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp 50 55 60 gaa gag gat gaa gac gac gat gag tgg gac 222 Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp 65 70 82 74 PRT Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 82 Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu 1 5 10 15 Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr 20 25 30 Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala 35 40 45 Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp 50 55 60 Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp 65 70 83 195 DNA Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 83 gct aat tta atg gcc agt atc aga gcc agc ggt ggt atg gat tta ctg 48 Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu 1 5 10 15 aaa agc agg aaa gta tct gct tct cct agt gtc gca tct aca aaa act 96 Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr 20 25 30 tcg aat cct ccg gta gaa gca ccc cct tct aac aat ctt atg gat gca 144 Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala 35 40 45 ttg gca agc gct ttg aac caa cgt aaa acc aaa gtc gct cag agt gac 192 Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp 50 55 60 gaa 195 Glu 65 84 65 PRT Artificial sequence Description of the artificial sequence Fragment of the homologuous protein WASP (Wsp1p) of Schizosaccharomyces pombe 84 Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu 1 5 10 15 Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr 20 25 30 Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala 35 40 45 Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp 50 55 60 Glu 65 

1. Use: of peptide fragments of WASP family proteins in eukaryotic cells, in particular in cells of humans or other mammals, or cells of insects or of micro-organisms such as yeasts, said peptide fragments having the property of WASP family proteins to polymerise actin, inducing cellular motility, or peptide sequences derived from the above-mentioned peptide fragments of WASP family proteins, in particular by substitution of one or more amino acids of these fragments, said derived sequences having the above-mentioned property of WASP family proteins and said fragments thereof, for the preparation of reagents which can be used within the framework of implementation of a process for the detection or screening of molecules having an inhibiting or stimulating effect on the formation of the actin cytoskeleton, and hence an inhibiting or stimulating effect on cellular motility.
 2. Use according to claim 1, of peptide fragments chosen from fragments: of human, or other mammalian WASP protein, in particular bovine or murine WASP protein, of human, or other mammalian N-WASP protein, in particular bovine or rat N-WASP protein, of Scar sub-family proteins, such as Scar1/WAVE protein of Dictyostellium discoideum, or of Caenorhabditis elegans, or of Drosophila melanogaster, of mice or of humans, of proteins of the Las sub-family of microorganisms, in particular yeasts such as the LAS17/Beel protein of Saccharomyces cerevisiae or WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe.
 3. Use according to claim 1 or 2, characterised in that the peptide fragments are chosen from those including: the verprolin homology domain contained in WASP family proteins, or in a protein derived from these, or at least one of the two verprolin homologous sequences when said WASP family proteins contain two of these sequences, or a peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to bind to actin, and the cofilin homology domain contained in WASP family proteins, or in a protein derived from these, or a peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to intervene in actin polymerisation.
 4. Use according to one of claims 1 to 3, of peptide fragments of WASP family proteins of human origin, chosen from the following: fragments of human WASP protein, themselves chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 430 and 446 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 469 and 487 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 404 to 430 in FIG. 1, and the C-terminal amino acid corresponds to that situated at one of positions 487 to 502 in FIG. 1, the fragment of 99 amino acids delimited by the amino acids situated at positions 404 and 502 in FIG. 1, i.e. the following SEQ ID NO: 4 peptide: Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu Asp Asp Glu Trp Asp Asp

the fragment of 84 amino acids delimited by the amino acids situated at positions 404 and 487 in FIG. 1, i.e. the following SEQ ID NO: 6 peptide: Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro Pro Ala Leu Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly

the fragment of 73 amino acids delimited by the amino acids situated at positions 430 and 502 in FIG. 1, i.e. the following SEQ ID NO: 8 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp

the fragment of 58 amino acids delimited by the amino acids situated at positions 430 and 487 in FIG. 1, i.e. the following SEQ ID NO: 10 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala Ile His Ser Ser Asp Glu Gly

fragments of human N-WASP protein, themselves chosen from: those including: the verprolin homologous sequence delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and/or the verprolin homologous sequence delimited by the amino acids situated at positions 433 and 449 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 392 to 433 in FIG. 2, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 2, the fragment of 114 amino acids delimited by the amino acids situated at positions 392 and 505 in FIG. 2, i.e. the following SEQ ID NO: 14 peptide: Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Len Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Gln Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Gln Asp Gln Asp Asp Gln Glu Asp Phe Gln Asp Asp Asp Glu Trp Gln Asp

the fragment of 97 amino acids delimited by the amino acids situated at positions 392 and 488 in FIG. 2, i.e. the following SEQ ID NO: 16 peptide: Pro Ser Asp Gly Asp His Gln Val Pro Thr Thr Ala Gly Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Gys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

the fragment of 101 amino acids delimited by the amino acids situated at positions 405 and 505 in FIG. 2, i.e. the following SEQ ID NO: 18 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

the fragment of 84 amino acids delimited by the amino acids situated at positions 405 and 488 in FIG. 2, i.e. the following SEQ ID NO: 20 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

the fragment of 73 amino acids delimited by the amino acids situated at positions 433 and 505 in FIG. 2, i.e. the following SEQ ID NO: 22 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

the fragment of 56 amino acids delimited by the amino acids situated at positions 433 and 488 in FIG. 2, i.e. the following SEQ ID NO: 24 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Alu Ile His Ser Ser Asp Glu Asp

fragments of human Scar1 protein, themselves chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 497 and 513 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 531 and 546 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 433 to 497 in FIG. 3, and the C-terminal amino acid corresponds to that situated at one of positions 546 to 559 in FIG. 3, the fragment of 117 amino acids delimited by the amino acids situated at positions 443 and 559 in FIG. 3, i.e. the following SEQ ID NO: 28 peptide: Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu

the fragment of 104 amino acids delimited by the amino acids situated at positions 443 and 546 in FIG. 3, i.e. the following SEQ ID NO: 30 peptide: Val Thr Val Thr Ala Leu Ala His Pro Pro Ser Gly Leu His Pro Thr Pro Ser Thr Ala Pro Gly Pro His Val Pro Leu Met Pro Pro Ser Pro Pro Ser Gln Val Ile Pro Ala Ser Glu Pro Lys Arg His Pro Ser Thr Leu Pro Val Ile Ser Asp Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser

the fragment of 63 amino acids delimited by the amino acids situated at positions 497 and 559 in FIG. 3, i.e. the following SEQ ID NO: 32 peptide: Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser Glu Asp Asp Ser Glu Phe Asp Glu Val Asp Trp Leu Glu

the fragment of 50 amino acids delimited by the amino acids situated at positions 497 and 546 in FIG. 3, i.e. the following SEQ ID NO: 34 peptide: Ala Arg Ser Val Leu Leu Glu Ala Ile Arg Lys Gly Ile Gln Leu Arg Lys Val Glu Glu Gln Arg Glu Gln Glu Ala Lys His Glu Arg Ile Glu Asn Asp Val Ala Thr Ile Leu Ser Arg Arg Ile Ala Val Glu Tyr Ser Asp Ser

or the peptide sequences derived from the above-mentioned peptide fragments, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the property defined in claim 1, of WASP family proteins and said fragments thereof.
 5. Use according to one of claims 1 to 3, of peptide fragments of WASP family proteins of non-human origin chosen from: fragments of non-human mammalian WASP family proteins chosen from the following: fragments of murine WASP protein, themselves chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 448 and 465 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 487 and 505 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 420 to 448 in FIG. 4, and the C-terminal amino acid corresponds to that situated at one of positions 505 to 520 in FIG. 4, the fragment of 101 amino acids delimited by the amino acids situated at positions 420 and 520 in FIG. 4, i.e. the following SEQ ID NO: 38 peptide: Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp Asp Glu Trp Asp Asp

the fragment of 86 amino acids delimited by the amino acids situated at positions 420 and 505 in FIG. 4, i.e. the following SEQ ID NO: 40 peptide: Pro Pro Pro Cys Pro Gly Ser Gly Pro Ala Pro Pro Pro Leu Pro Pro Thr Pro Val Ser Gly Gly Ser Pro Ala Pro Gly Gly Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly

the fragment of 73 amino acids delimited by the amino acids situated at positions 448 and 520 in FIG. 4, i.e. the following SEQ ID NO: 42 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly Glu Asp Gln Thr Gly Glu Asp Glu Glu Asp Asp Glu Trp Asp Asp

the fragment of 58 amino acids delimited by the amino acids situated at positions 448 and 505 in FIG. 4, i.e. the following SEQ ID NO: 44 peptide: Gly Arg Gly Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro Gly Ala Leu Glu Asn Ser Val Gln Gln Pro Pro Ala Gln Gln Ser Glu Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Val Ile His Ser Ser Asp Glu Gly

fragments of rat N-WASP protein, themselves chosen from: those including: the verprolin homologous sequence delimited by the amino acids situated at positions 401 and 417 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and/or the verprolin homologous sequence delimited by the amino acids situated at positions 429 and 444 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 466 and 484 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 401 to 429 in FIG. 5, and the C-terminal amino acid corresponds to that situated at one of positions 484 to 501 in FIG. 5, the fragment of 101 amino acids delimited by the amino acids situated at positions 401 and 501 in FIG. 5, i.e. the following SEQ ID NO: 48 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp Asp Glu Trp Glu Asp

the fragment of 84 amino acids delimited by the amino acids situated at positions 401 and 484 in FIG. 5, i.e. the following SEQ ID NO: 50 peptide: Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

the fragment of 73 amino acids delimited by the amino acids situated at positions 429 and 501 in FIG. 5, i.e. the following SEQ ID NO: 52 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Asp Asp Asp Glu Glu Asp Phe Gln Asp Asp Asp Glu Trp Glu Asp

the fragment of 56 amino acids delimited by the amino acids situated at positions 429 and 484 in FIG. 5, i.e. the following SEQ ID NO: 54 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Ser Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

fragments of bovine N-WASP protein, themselves chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and/or the verprolin homology domain delimited by the amino acids situated at positions 433 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 56 of bovine WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 405 to 433 in FIG. 6, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 6, the fragment of 101 amino acids delimited by the amino acids situated at positions 405 and 505 in FIG. 6, i.e. the following SEQ ID NO: 58 peptide: Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

the fragment of 84 amino acids delimited by the amino acids situated at positions 405 and 488 in FIG. 6, i.e. the following SEQ ID NO: 60 peptide: Ser Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

the fragment of 73 amino acids delimited by the amino acids situated at positions 433 and 488 in FIG. 6, i.e. the following SEQ ID NO: 62 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Asp Glu Asp Phe Glu Asp Asp Asp Glu Trp Glu Asp

the fragment of 56 amino acids delimited by the amino acids situated at positions 433 and 488 in FIG. 6, i.e. the following SEQ ID NO: 64 peptide: Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys Ser Val Thr Asp Ala Pro Glu Ser Thr Pro Pro Ala Pro Ala Pro Thr Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys Ala Ile His Ser Ser Asp Glu Asp

fragments of WASP family proteins of micro-organisms, such as: fragments of Saccharomyces cerevisiae Las17 protein, themselves chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 447 and 466 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 607 and 624 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 422 to 447 in FIG. 7, and the C-terminal amino acid corresponds to that situated at one of positions 624 to 633 in FIG. 7, the fragment of 212 amino acids delimited by the amino acids situated at positions 422 and 633 in FIG. 7, i.e. the following SEQ ID NO: 68 peptide: Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gin Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp Met Asp Asn Gly Asp Asp Trp

the fragment of 203 amino acids delimited by the amino acids situated at positions 422 and 624 in FIG. 7, i.e. the following SEQ ID NO: 70 peptide: Ser Asn Met Ser Ser Pro Pro Pro Pro Pro Val Thr Thr Phe Asn Thr Leu Thr Pro Gln Met Thr Ala Ala Thr Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His

the fragment of 187 amino acids delimited by the amino acids situated at positions 447 and 633 in FIG. 7, i.e. the following SEQ ID NO: 72 peptide: Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Gly Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His Asp Asp Met Asp Asn Gly Asp Asp Trp

the fragment of 178 amino acids delimited by the amino acids situated at positions 447 and 624 in FIG. 7, i.e. the following SEQ ID NO: 74 peptide: Gly Gln Pro Ala Val Pro Leu Pro Gln Asn Thr Gln Ala Pro Ser Gln Ala Thr Asn Val Pro Val Ala Pro Pro Pro Pro Pro Ala Ser Leu Gly Gln Ser Gln Ile Pro Gln Ser Ala Pro Ser Ala Pro Ile Pro Pro Thr Leu Pro Ser Thr Thr Ser Ala Ala Pro Pro Pro Pro Pro Ala Phe Leu Thr Gln Gln Pro Gln Ser Gly Gly Ala Pro Ala Pro Pro Pro Pro Pro Gln Met Pro Ala Thr Ser Thr Ser Gly Gly Gly Ser Phe Ala Glu Thr Thr Gly Asp Ala Gly Arg Asp Ala Leu Leu Ala Ser Ile Arg Gly Ala Gly Gly Ile Gly Ala Leu Arg Lys Val Asp Lys Ser Gln Leu Asp Lys Pro Ser Val Leu Leu Gln Glu Ala Arg Gly Glu Ser Ala Ser Pro Pro Ala Ala Ala Gly Asn Gly Gly Thr Pro Gly Giy Pro Pro Ala Ser Leu Ala Asp Ala Leu Ala Ala Ala Leu Asn Lys Arg Lys Thr Lys Val Gly Ala His

fragments of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe, themselves chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 501 and 517 of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 548 and 565 of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 477 to 501 in FIG. 8, and the C-terminal amino acid corresponds to that situated at one of positions 565 to 574 in FIG. 8, the fragment of 98 amino acids delimited by the amino acids situated at positions 477 and 574 in FIG. 8, i.e. the following SEQ ID NO: 78 peptide: Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp

the fragment of 89 amino acids delimited by the amino acids situated at positions 477 and 565 in FIG. 8, i.e. the following SEQ ID NO: 80 peptide: Pro Pro Ala Pro Ala Pro Ala Pro Ala Ala Pro Val Ala Ser Ile Ala Glu Leu Pro Gln Gln Asp Gly Arg Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu

the fragment of 74 amino acids delimited by the amino acids situated at positions 501 and 574 in FIG. 8, i.e. the following SEQ ID NO: 82 peptide: Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu Glu Asp Glu Asp Asp Asp Glu Trp Asp

the fragment of 65 amino acids delimited by the amino acids situated at positions 501 and 565 in FIG. 8, i.e. the following SEQ ID NO: 84 peptide: Ala Asn Leu Met Ala Ser Ile Arg Ala Ser Gly Gly Met Asp Leu Leu Lys Ser Arg Lys Val Ser Ala Ser Pro Ser Val Ala Ser Thr Lys Thr Ser Asn Pro Pro Val Glu Ala Pro Pro Ser Asn Asn Leu Met Asp Ala Leu Ala Ser Ala Leu Asn Gln Arg Lys Thr Lys Val Ala Gln Ser Asp Glu

the peptide sequences derived from the above-mentioned peptide fragments, in particular by substitution, addition or removal of one or more amino acids of these fragments, said derived sequences having the property defined in claim 1, of WASP family proteins and said fragments thereof.
 6. Peptide fragments of WASP family proteins in eukaryotic cells, in particular in cells of humans or other mammals, or cells of insects or of micro-organisms such as yeasts, chosen from those including: the verprolin homology domain contained in WASP family proteins, or in a protein derived from the latter, or at least one of the two verprolin homologous sequences when said WASP family proteins contain two of these sequences, or one peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to bind to actin, and the cofilin homology domain contained in WASP family proteins, or in a protein derived from the latter, or a peptide sequence derived from the above-mentioned domain, in particular by substitution, addition or removal of one or more amino acids, and retaining the property of this domain to intervene in the polymerisation of actin, or peptide sequences derived as defined in claim 1, from the above-mentioned peptide fragments of WASP family proteins, to the exclusion: of the peptide fragment of human WASP protein delimited by the amino acids situated at positions 429 to 503 of the peptide sequence represented in FIG. 1, of the peptide fragment of human WASP protein delimited by the amino acids situated at positions 187 to 489 of the peptide sequence represented in FIG. 1, of the peptide fragment of human WASP protein delimited by the amino acids situated at positions 422 to 489 of the peptide sequence represented in FIG. 1, of the peptide fragment of human N-WASP protein delimited by the amino acids situated at positions 392 to 505 of the peptide sequence represented in FIG. 2, of the peptide fragment of human Scar1 protein delimited by the amino acids situated at positions 443 to 559 of the peptide sequence represented in FIG. 3, of the peptide fragment of bovine N-WASP protein delimited by the amino acids situated at positions 392 to 505, and that delimited by the amino acids situated at positions 392 to 485 of the peptide sequence represented in FIG.
 6. 7. Peptide fragments according to claim 6, of human WASP protein, said fragments being chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 430 and 446 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 469 and 487 of the peptide sequence SEQ ID NO: 2 of human WASP protein represented in FIG. 1, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 404 to 430 in FIG. 1, and the C-terminal amino acid corresponds to that situated at one of positions 487 to 502 in FIG. 1, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10 peptides, or the sequences derived from the latter as defined in claim
 4. 8. Peptide fragments according to claim 6, of human N-WASP protein, said fragments being chosen from: those including: the verprolin homologous sequence delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and/or the verprolin homologous sequence delimited by the amino acids situated at positions 433 and 449 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 12 of human N-WASP protein represented in FIG. 2, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 392 to 433 in FIG. 2, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 2, the above-mentioned SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 24 peptides, or sequences derived from these, as defined in claim
 4. 9. Peptide fragments according to claim 6, of human Scar1 protein, said fragments being chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 497 and 513 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 531 and 546 of the peptide sequence SEQ ID NO: 26 of human Scar1 protein represented in FIG. 3, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 443 to 497 in FIG. 3, and the C-terminal amino acid corresponds to that situated at one of positions 546 to 559 in FIG. 3, the above-mentioned SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, and SEQ ID NO: 34 peptides, or sequences derived from these, as defined in claim
 4. 10. Peptide fragments according to claim 6, of murine WASP protein, said fragments being chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 448 and 465 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 487 and 505 of the peptide sequence SEQ ID NO: 36 of murine WASP protein represented in FIG. 4, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 420 to 448 in FIG. 4, and the C-terminal amino acid corresponds to that situated at one of positions 505 to 520 in FIG. 4, the above-mentioned SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, and SEQ ID NO: 44 peptides, or sequences derived from these, as defined in claim
 4. 11. Peptide fragments according to claim 6, of rat N-WASP protein, said fragments being chosen from: those including: the verprolin homologous sequence delimited by the amino acids situated at positions 401 and 417 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and/or the verprolin homologous sequence delimited by the amino acids situated at positions 429 and 444 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain contained in the above-mentioned N-WASP protein, i.e. the domain delimited by the amino acids situated at positions 466 and 484 of the peptide sequence SEQ ID NO: 46 of rat N-WASP protein represented in FIG. 5, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 401 to 429 in FIG. 5, and the C-terminal amino acid corresponds to that situated at one of positions 484 to 501 in FIG. 5, the above-mentioned SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, and SEQ ID NO: 54 peptides, or sequences derived from these, as defined in claim
 4. 12. Peptide fragments according to claim 6, of bovine N-WASP protein, said fragments being chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 405 and 421 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and/or the verprolin homology domain delimited by the amino acids situated at positions 433 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 470 and 488 of the peptide sequence SEQ ID NO: 56 of bovine N-WASP protein represented in FIG. 6, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 405 to 433 in FIG. 6, and the C-terminal amino acid corresponds to that situated at one of positions 488 to 505 in FIG. 6, the above-mentioned SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, and SEQ ID NO: 64 peptides, or sequences derived from these, as defined in claim
 4. 13. Peptide fragments according to claim 6, of Saccharomyces cerevisiae Las17 protein, said fragments being chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions 447 and 466 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions 607 and 624 of the peptide sequence SEQ ID NO: 66 of Las17 protein represented in FIG. 7, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions 422 to 447 in FIG. 7, and the C-terminal amino acid corresponds to that situated at one of positions 624 to 633 in FIG. 7, and more particularly the above-mentioned SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74 peptides, or sequences derived from these, as defined in claim
 4. 14. Peptide fragments according to claim 6, of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe, said fragments being chosen from: those including: the verprolin homology domain delimited by the amino acids situated at positions ??? and ??? of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, and the cofilin homology domain delimited by the amino acids situated at positions ??? and ??? of the peptide sequence SEQ ID NO: 76 of WASP homologous protein (Wsp1p) of Schizosaccharomyces pombe represented in FIG. 8, or a peptide sequence derived from the above-mentioned domain as defined in claim 3, fragments of which the N-terminal amino acid corresponds to that situated at one of positions ??? to ??? in FIG. 8, and the C-terminal amino acid corresponds to that situated at one of positions ??? to ??? in FIG. 8, the above-mentioned SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, and SEQ ID NO: 84 peptides, or sequences derived from these, as defined in claim
 4. 15. Nucleotide sequences coding for the peptide fragments, or for the proteins derived from the latter, defined in one of claims 6 to
 14. 16. Reagent for the implementation of a process for the detection or screening of molecules having an inhibiting or stimulating effect on the formation of the actin cytoskeleton, and hence an inhibiting or stimulating effect on cellular motility, said reagent comprising at least one peptide fragment defined in one of claims 1 to 14, bound or adsorbed to a support capable of moving under the effect of actin polymerisation, when said support bound to said fragment is placed in a medium containing the elements necessary for actin polymerisation, in particular when said support is added to an extract prepared from supernatants of lysed cells from the organism.
 17. Reagent according to claim 16, characterised in that it is chosen from microspheres whose diameter is between approx. 100 nm and approx. 10,000 nm, the material constituting the microspheres itself being chosen from polystyrenes or latex, said microspheres each containing approx. 5,000 to approx. 50,000 molecules of fragment or sequence derived according to one of claims 1 to
 14. 18. Process for the detection or screening of molecules, having an inhibiting or stimulating effect on the formation of the actin cytoskeleton, and hence an inhibiting or stimulating effect on cellular motility, said process comprising: a stage of placing the tested molecule in the presence of a reagent according to claim 16 or 17, into a medium containing actin and the elements necessary for actin polymerisation, in particular into an extract of supernatant of lysed cells, followed by the eventual detection of inhibition or activation of the actin polymerisation process on the surface of said reagent, compared with a control, respectively demonstrating an inhibiting or stimulating effect on the formation of the actin cytoskeleton.
 19. Process according to claim 18, applied to the detection or screening of molecules: capable of being used as medicaments in the treatment of pathologies linked to a dysfunction of the actin polymerisation process within the context of formation of the actin cytoskeleton, in particular as medicaments in the treatment of metastatic cancers, or as anti-parasitic antiobiotics, or capable of having a cytotoxic effect corresponding to inhibition or stimulation of the formation of the actin cytoskeleton.
 20. Kit for implementation of a process according to claim 18 or 19, comprising a reagent according to claim 16 or 17, possibly a marked compound enabling polymerisation of actin to be made visible, in particular actin marked with fluorescence, possibly an appropriate medium containing the elements necessary for actin polymerisation, in particular an extract of lysed cells. 